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Unduplicated	Total	All	Mandates 1,912.96$																			 46.94$																			 52.74$														 796.81$														 0.43% 6.45%
Mandates	with	Potential	Marginal	Direct	Cost
Service	Mandates
Autism	Spectrum	Disorders	Services 39.54$																								 15.25$																			 17.13$														 44.42$																 0.14% 0.36%
Chiropractic	Services 2.68$																											 0.94$																					 1.06$																 3.01$																		 0.01% 0.02%
Child	Hearing	Aids 6.89$																											 -$																							 -$																		 7.74$																		 0.00% 0.06%
Cleft	Palate	and	Lip 3.30$																											 0.10$																					 0.12$																 3.70$																		 0.00% 0.03%
Diabetes-related	Services	and	Supplies 175.79$																						 -$																							 -$																		 197.52$														 0.00% 1.60%
Early	Intervention	Services 25.72$																								 2.78$																					 3.12$																 28.90$																 0.03% 0.23%
Home	Health	Care 257.25$																						 -$																							 -$																		 289.04$														 0.00% 2.34%
Hormone	Replacement	Therapy	(HRT) 11.56$																								 0.74$																					 0.83$																 12.99$																 0.01% 0.11%
Human	Leukocyte	Antigen	Testing 0.02$																											 -$																							 -$																		 0.02$																		 0.00% 0.00%
Hypodermic	Syringes	or	Needles 1.08$																											 -$																							 -$																		 1.22$																		 0.00% 0.01%
Infertil ity	Treatment 104.73$																						 12.67$																			 14.24$														 117.67$														 0.12% 0.95%
Low	Protein	Food	Products	for	Inherited	Amino	
			Acid	and	Organic	Acid	Diseases	(PKU)
Nonprescription	Enteral	Formulas 0.92$																											 -$																							 -$																		 1.04$																		 0.00% 0.01%
Oral	Cancer	Drugs 1.38$																											 0.49$																					 0.55$																 1.55$																		 0.00% 0.01%
Prosthetic	Limbs	and	Associated	Services 3.87$																											 -$																							 -$																		 4.35$																		 0.00% 0.04%
Scalp	Hair	Prostheses	for	Cancer	Patients 0.41$																											 -$																							 -$																		 0.46$																		 0.00% 0.00%
Speech,	Hearing	and	Language	Disorders 7.12$																											 -$																							 -$																		 8.00$																		 0.00% 0.06%
Provider	Mandates
Certified	Nurse	Midwives 1.62$																											 -$																							 -$																		 1.83$																		 0.00% 0.01%
Certified	Registered	Nurse	Anesthetists 22.09$																								 -$																							 -$																		 24.83$																 0.00% 0.20%
Chiropractors 7.97$																											 0.81$																					 0.91$																 8.96$																		 0.01% 0.07%
Dentists 1.39$																											 -$																							 -$																		 1.56$																		 0.00% 0.01%
Nurse	Practitioners 44.63$																								 9.31$																					 10.46$														 50.15$																 0.08% 0.41%
Optometrists 6.23$																											 -$																							 -$																		 7.00$																		 0.00% 0.06%
Physician	Assistants 41.01$																								 2.01$																					 2.26$																 46.07$																 0.02% 0.37%
Podiatrists 16.38$																								 0.81$																					 0.91$																 18.41$																 0.01% 0.15%
Mandates	Judged	to	Have	Zero	Marginal	Cost
Bone	Marrow	Transplants	for	Treatment	of	Breast	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Cardiac	Rehabilitation 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Clinical	Trials	(to	treat	cancer) 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Contraceptive	Services 94.20$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Cytologic	Screening 17.54$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Hearing	Screening	for	Newborns 3.32$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Hospice	Care 16.49$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Lead	Poisoning	Screening 1.20$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Mammography 17.69$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Maternity	Health	Care	(including	minimum	maternity	stay) 471.27$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Mental	Health	Care 455.40$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Preventive	Care	for	Children	Up	to	Age	Six	 122.14$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	HIV/AIDS -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
0.01%1.53$																											 0.08$																					 1.71$																		0.09$																 0.00%
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The	initial	range	of	the	marginal	direct	cost	impact	of	all	39	mandate	laws	studied,	including	administrative	costs,	is	therefore	between	$52.7	million	and	$796.8	million.		However,	the	true	value	is	not	likely	to	be	near	either	end	of	this	range.		The	upper	bound	estimate	includes	all	RDCs	except	those	for	mandates	judged	likely	to	have	zero	marginal	costs,	and	so	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	eliminate	all	mandated	benefits	completely	in	the	absence	of	the	mandate	laws.		This	is	very	unlikely	to	be	true	or	close	to	true	given	that	$469.4	million	of	this	amount	(about	59	percent;	these	figures	are	net	of	mandate	overlaps)	is	composed	of	two	mandates--home	health	services	and	diabetes	services	and	supplies--that	would	likely	be	provided	as	cost-effective	benefits,	even	if	at	somewhat	lower	levels.	The	lower	bound	marginal	cost	estimate	for	each	mandate	judged	to	have	potential	marginal	direct	costs	is	derived	by	comparing	the	allowed	amounts	per	person	approved	by	insurers	for	the	fully-insured	sample	to	the	allowed	amounts	for	the	self-insured	sample	(which	is	not	subject	to	the	mandates).		Cases	in	which	the	self-insured	spending	per	person	is	higher	are	ignored,	and	the	differences,	net	of	mandate	overlaps,	for	the	remaining	cases	in	which	the	fully-insured	costs	per	person	are	higher	are	summed	to	calculate	the	overall	lower	bound	mandate	marginal	cost.		This	lower	bound	estimate	assumes	that	100	percent	of	the	spending	for	the	mandates	in	the	self-insured	market	would	occur	in	the	absence	of	the	mandate	laws,	and	that	none	of	the	spending	is	influenced	by	the	mandated	spending	levels	in	the	fully-insured	market.		This,	too,	is	very	unlikely	to	be	true	or	close	to	true,	owing	to	the	upward	pressure	mandates	in	the	fully-insured	market	place	on	benefits	offered	by	self-insured	plans.			This	reasoning	supports	narrowing	the	range	of	the	mandate	law	impact.		Table	E2	displays	medical	costs	in	the	fully-insured	population	for	each	percent	of	premium	in	the	$60	million	to	$800	million	range.		While	the	scope	of	this	study	does	not	allow	a	direct	empirical	basis	for	narrowing	the	range,	the	actual	direct	cost	impact	is	likely	to	be	somewhere	in	the	middle	part	of	the	range.		As	self-insured	employers	must	compete	in	the	labor	market	with	fully-insured	employers	whose	health	insurance	policies	must	include	the	mandated	benefits,	self-insured	benefits	are	likely	to	be	significantly	influenced	by	the	presence	of	the	mandate	laws	and	the	laws’	effect	on	benefit	structures	at	competing	employers.		While	there	are	potential	effects	that	could	cause	the	lower	bound	to	be	over-estimated,	on	net	it	is	likely	that	the	0.43	percent	of	premium	in	fully-insured	cost	levels	over	and	above	self-insured	cost	levels	significantly	understates	the	true	impact.		At	the	same	time,	federal	benefit	requirements	would	remain	even	if	state	mandates	were	repealed,	and	it	is	unlikely	that	popular	and/or	cost-effective	benefits	like	diabetes	care	would	be	completely	removed	from	policies	if	the	mandate	laws	were	not	in	place,	making	6.45	percent	of	premium	(which	assumes	all	costs	of	the	25	potential	marginal	cost	mandates	are	marginal)	a	certain	overstatement	of	the	impact.		Based	on	the	foregoing	discussion,	mid-range	estimates	in	the	one	to	four	percent	of	premium	(roughly	$125	million	to	$500	million	annually)	range,	while	not	directly	empirically	supported	by	this	analysis,	may	be	a	logically	inferable	estimate	of	the	marginal	impact	on	health	care	costs	directly	associated	with	the	covered	benefits	described	in	the	mandate	laws.	
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estimate	of	the	marginal	cost	introduced	by	the	mandate	legislation.		Previous	research	has	found	that	benefit	levels,	including	for	mandated	services,	are	similar,	if	not	richer,	in	the	self-insured	market.18		Mandate	laws	may	have	small	effects	to	the	extent	these	research	findings	indicate	firms	offer	the	benefits	voluntarily.		However,	considering	that	employers	in	Massachusetts	that	self-insure	must	compete	in	the	labor	market	with	fully-insured	firms	that	must	offer	the	mandated	benefit	package	and	public-sector	employers	offering	GIC	plans	that	voluntarily	include	all	mandated	health	insurance	benefits	(even	when	the	text	of	the	mandate	laws	does	not	reach	the	self-insured	GIC),	the	benefits	in	the	self-insured	firms	are	likely	to	be	at	least	somewhat	richer	than	they	would	be	in	the	absence	of	the	mandate	laws.		This	competitive	labor	market	effect	would	shrink	the	cost	difference	between	fully-insured	and	self-insured	plans	and	understate	(or	provide	a	lower	bound	for)	the	implied	impact	of	benefit	laws	on	health	care	costs	provided	by	the	difference	between	fully-insured	and	self-insured	costs.	In	the	cost	estimates	displayed	in	the	Results	section,	these	lower-bound	estimates	are	derived	from	the	difference	between	insurer	spending	in	the	fully-insured	population	for	the	mandated	benefit	and	the	insurer	spending	in	the	self-insured	population	for	the	same	benefit.		To	reduce	the	impact	that	differences	in	average	patient	cost	sharing	between	these	populations	may	have	on	the	result,	the	calculation	is	performed	by	computing	the	percentage	by	which	the	fully-insured	allowed	(before	cost	sharing)	PMPM	exceeds	the	self-insured	allowed	PMPM,	and	applying	that	percentage	to	the	fully-insured	paid	PMPM.		The	result	is	a	lower-bound	estimate	of	the	impact	of	the	mandate	on	fully-insured	paid	expenditures.		Where	the	self-insured	allowed	PMPM	is	higher	than	the	fully-insured	allowed	PMPM,	we	treat	the	impact	as	zero,	rather	than	negative;	we	assume	that	if	self-insured	firms	on	average	have	a	higher	spending	level	than	fully-insured	products	subject	to	the	mandates,	it	is	not	caused	by	the	existence	of	the	mandate.		That	is:	Lower	Bound	Marginal	Cost	=	[(FIv	Allowed	–	SI	Allowed)/FI	Allowed]*FI	paid	RDC,	if	FI	Allowed	–	SI	Allowed	>	0	Lower	Bound	Marginal	Cost	=	0,	otherwise	An	upper-bound	claim	cost	estimate	is	also	provided	for	each	mandate,	which	includes	the	entire	RDC,	except	for	those	mandates	judged	by	the	carriers	likely	to	have	zero	marginal	costs.		This	upper-bound	estimate	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	pay	zero	dollars	in	claims	for	the	services	described	by	the	mandates	in	the	absence	of	the	mandate	laws.		For	most	mandates	there	is	good	reason	to	believe	the	actual	marginal	cost	is	far	lower,	though	we	do	not	have	a	direct	method	of	estimating	by	how	much.		For	example,	home	health	care	services	are	widely	considered	to	be	cost-effective	in	many	contexts.		In	all	likelihood	carriers	would	cover	this	benefit,	if	at	a	somewhat	lower	level,	in	the	absence	of	the	mandate.		As	a	result,	the	upper	bound	estimates	are	likely	to	be	well	above	the	actual	marginal	direct	cost.	To	calculate	the	total	cost	of	the	mandates	to	the	Massachusetts	health	care	system,	administrative	loading	(the	additional	costs	over	and	above	health	care	claims	required	to	administer	the	health																																									 																					v	In	this	and	other	equations	and	exhibits	in	this	report,	the	abbreviation	“FI”	refers	to	the	fully-insured	and	self-insured	GIC	population	subject	to	the	mandates,	and	“SI”	refers	to	the	non-GIC	self-insured	comparison	population.	
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Autism	Spectrum	Disorders	The	autism	mandate	requires	coverage	for	treatment	for	Autism	spectrum	disorders	(ASDs)	on	a	“non-discriminatory	basis”,	meaning	on	the	same	terms	as	coverage	for	medical/surgical	conditions.		The	mandate	includes	in	the	treatment	of	ASDs:	habilitative	or	rehabilitative	care,	pharmacy	care,	psychiatric	care,	psychological	care,	and	therapeutic	care.		Coverage	for	psychiatric	and	psychological	care	is	also	required	by	the	mental	health	mandate.		The	mandate’s	primary	effect	is	to	require	coverage	for	medically-necessary	habilitative	care,	i.e.,	“professional,	counseling,	and	guidance	services	and	treatment	programs,	including	applied	behavior	analysis	supervised	by	a	Board	Certified	Behavior	Analyst.”25	Effect	of	the	mandate	on	health	ASDs	are	a	group	of	developmental	disabilities	characterized	by	persistent	impaired	social	interaction	and	communication	and	by	restricted	and	repetitive	patterns	of	behavior,	interests,	or	activities	present	in	early	developmental	stages	that	clinically	and	significantly	impair	social,	occupational,	or	other	areas	of	functioning.26,27		This	definition	incorporates	several	previously	distinct	diagnoses,	including	autism,	Asperger’s	disorder,	childhood	disintegrative	disorder,	and	pervasive	developmental	disorder	not	otherwise	specified.28	In	general,	children	with	autism	are	less	able	to	interpret	non-verbal	social	and	emotional	cues,	as	they	struggle	to	interpret	behaviors	such	as	body	language	and	facial	expressions.		They	also	struggle	with	reciprocal	social	interaction,	exhibit	inflexibility	in	their	behaviors,	have	difficulty	coping	with	change,	and	engage	in	restricted	and	repetitive	behaviors.29		While	these	behaviors	and	symptoms	may	change	over	time,	adults	with	ASD	continue	to	struggle	throughout	life	with:	language,	especially	perspective,	nuance,	humor,	and	implied	meanings;	self-sufficiency;	and	social	skills.	30		Adults	with	autism	are	much	less	likely	to	be	fully	self-supporting,	and	many	develop	psychiatric	issues	such	as	obsessive-compulsive	disorder	or	affective	disorders.31		ASDs	require	chronic	management	and	cannot	be	cured.		Outcomes	and	behaviors	for	individuals	change	over	time,	but	most	patients	remain	on	the	spectrum	as	adults.		ASDs	affect	a	person’s	mental	health,	as	well	as	his	ability	to	achieve	academically,	live	independently,	obtain	and	retain	employment,	and	establish	and	maintain	positive	social	relationships.32		Additionally,	ASD	patients	may	have	an	increased	incidence	of	seizure	and	gastrointestinal	disorders,	as	well	as	sleep	disturbances,	which	must	also	be	addressed	through	appropriate	medical	management.33	ASD	is	difficult	to	diagnose,	as	it	is	“a	neurodevelopmental	disability	or	phenomenological	disorder,	not	a	specific	disease.”34		Moreover,	while	symptoms	and	signs	are	usually	apparent	early	in	a	child’s	development,	the	behavior	patterns	and	social	deficits	may	not	be	identified	as	ASD	until	social,	occupational,	educational,	or	other	developmental	milestones	are	not	met.35		Variations	in	functional	limitations,	as	well	as	the	pattern	of	development,	also	contribute	to	difficulties	with	diagnosis.36		For	the	general	population,	the	U.S.	Preventive	Services	Task	Force	(USPSTF)	–	an	independent	panel	of	national	experts	in	prevention	and	evidence-based	medicine	that	recommends	clinical	preventive	services	such	as	screenings,	counseling	services,	and	preventive	medications37	–	recently	released	its	report	on	screening	for	ASD	in	children	ages	18	to	30	months,	concluding	“current	evidence	is	insufficient	to	assess	the	balance	of	benefits	and	harms	of	screening	
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Report	Year	 200739	 200940	 201241	 201442	
Data	Year	 2002		 2006		 2008		 2010			
	 	 	 	 	
Prevalence		 1	in	152	 1	in	110	 1	in	88	 1	in	68	
Per	1000	children	 6.6	 9.0	 11.3	 14.7	
Change	versus	previous	 -	 36.4%	 25.6%	 30.1%	
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communication	therapies,	pharmacological	therapies	to	treat	symptoms,	dietary	approaches,	and	complementary	and	alternative	medicine	therapies.50		Additional	supports	are	also	used	by	those	diagnosed	with	autism,	and	may	change	over	time	depending	on	individual	age	and	need,	including	educational,	vocational,	residential,	and	housing	support	services.51	Behavioral	and	communication	interventions	are	the	primary	therapies	for	ASD.		Broadly,	they	address	communication,	social,	daily-living,	play,	and	leisure	skills,	as	well	as	academic	achievement	and	maladaptive	behaviors.		Interventions	are	structured	to	help	the	child	acquire	the	skills	and	knowledge	necessary	for	independence	and	personal	responsibility	in	a	variety	of	environments.52		These	types	of	therapies	should	provide	structure,	direction,	and	organization	for	the	child,	and	encourage	family	participation.53		Models	have	most	often	been	developed	upon	a	“primary	philosophical	orientation,”	frequently	categorized	as	behavior	analytic,	developmental,	or	structured	teaching.54	The	most	widely	used	and	researched	type	of	behavioral	therapy	for	ASD	is	applied	behavior	analysis	(ABA).55		Based	on	psychology	research	and	its	resultant	principles	of	learning,	these	interventions	focus	on	helping	patients	learn	positive	behaviors	and	decrease	negative	ones,	while	developing	adaptive	strategies	to	new	situations.56		ABA	emphasizes	evaluation	and	measurement	of	behaviors,	leading	researchers	to	most	easily	apply	scientific	methods	when	evaluating	these	interventions.		In	fact,	“most	studies	of	comprehensive	treatment	programs	that	meet	minimal	scientific	standards	involve	treatment	of	preschoolers	using	behavioral	approaches.”57	ABA	encompasses	a	variety	of	methodologies	including	Pivotal	Response	Training	(PRT),	Early	Intensive	Behavioral	Intervention	(EIBI)	and	Verbal	Behavior	Intervention	(VBI).58		One	popular	method,	Discrete	Trial	Training	(DTT),	teaches	behaviors	and	responses	step-by-step.		Environments	are	highly	structured	and	lessons	are	reduced	to	their	simplest	parts,	using	positive	reinforcement	for	desired	behaviors.59		A	similar	intervention	is	TEACCH,	or	Treatment	and	Education	of	Autistic	and	Related	Communication	Handicapped	Children	program,	also	known	as	“structured	teaching.”		This	intervention	focuses	on	modifying	the	patient’s	environment	to	accommodate	the	individual’s	deficits,	as	well	as	on	improving	skills.		Visual	cues,	schedules,	routines	and	structured	work	and	activity	systems	are	part	of	this	method.60		Research	has	found	that	while	these	methods	can	teach	certain	skills,	they	cannot	be	generalized	for	“spontaneous	use	in	natural	environments.”61		Other	types	of	behavioral	and	communication	interventions	include	Developmental,	Individual	Differences,	Relationship-Based	Approach	(DIR;	also	called	"Floortime")	and	Picture	Exchange	Communication	System	(PECS);	likewise,	sensory	integration,	occupational	and	speech	therapies	are	additional	approaches	to	treatment.62	No	drugs	are	currently	approved	specifically	for	the	treatment	of	ASD.63		However,	medications	are	used	to	treat	specific	symptoms	and	“maladaptive	behaviors	such	as	aggression,	self-injurious	behavior,	repetitive	behaviors	(e.g.,	perseveration,	obsessions,	compulsions,	and	stereotypic	movements),	sleep	disturbance,	mood	lability,	irritability,	anxiety,	hyperactivity,	inattention,	destructive	behavior,	or	other	disruptive	behaviors.”64		Although	dietary	approaches	and	alternative	medicine	therapies	are	widely	used,	in	general,	research	has	not	proven	their	effectiveness;65	in	fact,	some	therapies,	such	as	intravenous	chelation	of	heavy	metals,	have	been	shown	to	be	dangerous.66	
Comprehensive	Mandated	Benefit	Review	


















compass Health Analytics 15 December 2016 
associated	with	aggression,	self-injury,	or	other	challenging	behaviors.76		ABA	encompasses	a	wide	array	of	behavioral	interventions;	some	of	these	services	have	been	shown	to	be	effective	in	treating	certain	symptoms	in	certain	patients	with	ASD,	and	are	identified	more	specifically	in	the	previous	list	as	well	as	in	guidelines	reviewed	by	the	NPDC-ASD.77		Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).	Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.	These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	ABA,	are	left	to	the	states.78		This	analysis	will	assume	ABA	would	not	be	included	in	the	benchmark	plan	without	the	autism	services	mandate.		Such	services	are	absent	from	the	benchmark	plans	of	about	half	the	states,	suggesting	they	are	not	a	federal	requirement.79		In	addition,	the	definition	of	habilitative	was	even	less	well	fleshed-out	in	years	prior	to	2016,	which	make	up	the	measurement	period	for	this	analysis.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	reporting	an	ASD	diagnosis	and	a	procedure	code	indicating,	per	the	carrier	specification	review,	medically	necessary	ABA.		The	estimated	PMPM	RDC	paid	claim	amount	was	$1.39,	with	total	PMPM	cost,	after	administrative	loading,	of	$1.57	(or	0.36	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.56	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	cost	impact	estimate,	including	administrative	loading,	of	$0.60	PMPM,	or	0.14	percent	of	Commonwealth	premium.		Table	2	below	displays	a	summary	of	these	results	and	related	statistics.	
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Paid	PMPM 1.39$																 0.87$																 0.54$																
Paid	PMPM	With	Admin 1.57$																 0.98$																 0.60$																




























































Paid	PMPM 1.35$																 0.81$																 0.47$																
Paid	PMPM	With	Admin 1.52$																 0.91$																 0.53$																
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Effect	of	the	mandate	on	health	Orofacial	clefts,	the	collective	term	for	cleft	lip	and	cleft	palate,	are	birth	defects	that	occur	during	pregnancy	when	a	baby’s	lips	or	mouth	do	not	properly	join.109		During	the	fourth	to	seventh	weeks	of	pregnancy,	the	body	tissue	and	other	cells	from	the	sides	of	the	head	grow	toward	the	center	to	join	and	make	a	face,	creating	features	including	lips	and	mouth.110		If	the	tissue	around	the	lips	does	not	join	completely,	an	opening	known	as	a	cleft	lip	can	result	that	may	range	from	a	small	slit	to	a	large	gap	through	the	lip	into	the	nose;	this	may	occur	on	one	or	both	sides,	or	more	rarely,	in	the	middle.111		During	the	sixth	to	ninth	weeks	of	pregnancy,	the	bone,	muscle,	and	other	tissue	on	the	roof	of	the	mouth	forms	to	create	a	palate;	if	these	do	not	join	completely	together,	a	cleft	palate	is	formed,	and	can	include	the	front,	back,	or	both	parts	of	the	palate.112		Almost	70	percent	of	children	with	orofacial	clefts	have	both	cleft	palate	and	cleft	lip.113	Children	with	orofacial	clefts	often	have	problems	with	their	teeth,	feeding,	clear	speaking,	ear	infections,	and	hearing.114		They	are	also	more	likely	to	be	hospitalized	during	childhood	than	children	without	orofacial	clefts,	with	hospitalization	rates	higher	for	children	with	cleft	palate	present	than	for	children	with	cleft	lip	only.115,116		A	recent	study	also	found	that	children	born	with	orofacial	clefts	may	have	poorer	academic	outcomes	in	elementary	school	than	their	peers,	but	that	more	study	is	needed	to	confirm	results	and	track	outcomes	at	higher	grades.		The	study	does	not	differentiate	the	performance	of	children	based	on	their	level	of	cleft	repair.117	It	is	estimated	that	6.35	babies	per	10,000	are	born	annually	with	a	cleft	palate	without	cleft	lip	(1	in	1574),	and	a	total	of	10.6	babies	per	10,000	are	born	with	a	cleft	lip	with	or	without	a	cleft	palate	(1	in	940).118,119,120		Comparably,	as	of	2012,	9.2	babies	per	10,000	are	born	in	Massachusetts	with	an	orofacial	cleft.121		Isolated	orofacial	clefts,	occurring	without	another	major	birth	defect,	are	one	of	the	most	common	types	of	birth	defects	in	the	United	States,	and	comprise	approximately	75	percent	of	total	cases	of	children	with	birth	defects.122	While	the	causes	of	orofacial	clefts	are	unknown,	these	birth	defects	are	thought	to	be	the	result	of	a	combination	of	genetic	and	environmental	factors.		Babies	born	to	mothers	with	diabetes,	who	smoke	or	drink	alcohol,	or	who	use	certain	medications	during	the	first	trimester	of	pregnancy	face	an	increased	risk	of	orofacial	clefts.123,124		A	mother’s	healthy	diet	in	the	year	before	pregnancy	reduces	the	risk	of	orofacial	cleft,125	as	does	adequate	intake	of	folic	acid.126	Treatment	of	orofacial	clefts	vary	based	on	the	cleft’s	severity,	the	child’s	age,	needs,	and	other	birth	defects	or	syndromes	that	may	be	present.127		Surgical	repair	is	recommended	within	the	first	year	of	life	for	cleft	lip,	and	within	the	first	18	months	for	cleft	palate	(earlier	if	possible).128		Additional	surgeries	are	often	necessary	as	the	children	age,	including	those	to	improve	breathing,	hearing,	speech,	language	development,	and	appearance.129		Treatment	by	otorhinolaryngologists,	audiologists,	dentists,	orthodontists,	or	speech	or	language	therapists	may	also	be	necessary.130		Some	children	and	families	also	benefit	from	peer	and	other	emotional	support	resources.131		The	American	Cleft	Palate-Craniofacial	Association	recommends	that	children	with	orofacial	clefts	receive	treatment	through	specialized	cleft	and	craniofacial	teams	who	can	coordinate	the	variety	of	services	needed	throughout	infancy,	childhood,	adolescence,	and	if	necessary,	adulthood.132		Interdisciplinary	teams	include	health	professionals	from	medical,	dental,	surgical,	and	allied	health	
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Paid	PMPM 0.12$																 0.11$																 0.004$													
Paid	PMPM	With	Admin 0.13$																 0.13$																 0.004$													

















































Paid	PMPM 6.20$																 7.36$																 -$																		
Paid	PMPM	With	Admin 6.97$																 8.27$																 -$																		
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Early	intervention	is	a	group	of	services	and	supports	designed	to	help	children	gain	basic	skills,	usually	in	the	first	two	years	of	life,	including	physical,	mental,	communication,	social,	and	emotional.153		Services	often	include	physical,	occupational	and/or	speech	therapy,	family	training,	nutrition	services,	case	management,	referrals,	and	services	for	hearing	impairment.154		Each	state	provides	its	own	set	of	programs	and	services	to	children	from	birth	to	age	2	who	have	been	diagnosed	with	developmental	disease	or	disability,	under	Part	C	of	Public	Law	108-77:	Individuals	with	Disabilities	Education	Improvement	Act	(2004),	or	"IDEA."155		Some	states,	including	Massachusetts,	extend	these	services	to	children	only	at-risk	for	such	delays	and	disabilities,	and	continue	them	until	age	3.	Early	intervention	services	have	been	shown	to	prevent	developmental	delay,	as	measured	by	placement	in	special	education	as	well	as	retention	in	grade	when	a	child	reaches	school	age.156		Moreover,	it	is	“deemed	essential	to	prevent	mental	retardation	and	poor	intellectual	development	in	children	whose	families	do	not	provide	adequate	stimulation	in	the	early	years	of	life.”157		Improved	outcomes	in	health,	language	and	communication,	cognitive	and	social/emotional	development,	as	well	as	academic	achievement,	labor	market	success,	and	a	reduction	in	delinquency,	crime,	and	social	welfare	program	use,	have	been	shown	in	children	who	receive	high	quality	early	intervention	services.158,159,160	Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).	Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.	These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	early	intervention	services,	are	unclear	on	the	surface	and	left	to	the	states.161		For	reasons	cited	in	the	overview	of	the	methodology,	this	analysis	assumes	federal	EHB	requirements	do	not	address	state-mandated	early	intervention	services.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	specifically	identified	early	intervention	procedure	codesxi	plus	all	claims	for	evaluation	and	management	procedures	performed	by	certified	early	intervention	providersxii	for	members	under	three	years	of	age	in	the	target	population	and	period.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.91,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.02	(or	0.23	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	these	services	were	found	to	be	$0.10	lower	than	fully-insured	PMPM	allowed	expenses,	including																																									 																					xi	HCPCS	codes	96153,	H0031,	H0032,	H2012,	H2015,	H2019,	T1015,	T1023,	T1024,	T1025,	T1026,	and	T1027.	xii	Plans	differ	in	the	method	used	to	identify	EI	providers	in	their	claims	systems:	Some	plans	use	specific	early	intervention	procedure	code	modifiers,	others	use	an	early	intervention	provider	type	code.		Compass	extracted	claims	from	the	MA	APCD	extract	based	on	carrier-specific	rules	provided	in	the	carrier	specification	review.		
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Paid	PMPM 0.91$																 0.79$																 0.10$																
Paid	PMPM	With	Admin 1.02$																 0.88$																 0.11$																




















































Paid	PMPM 0.24$																 0.30$																 -$																		
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Effect	of	the	mandate	on	health	Menopause	is	the	phase	in	a	woman’s	life	in	which	menstruation	naturally	stops,	marking	the	end	of	her	reproductive	years.203		During	her	reproductive	phase,	a	woman’s	ovaries	produce	the	hormones	estrogen	and	progesterone	to	control	the	menstrual	cycle.		During	the	perimenopausal	years	leading	up	to	menopause,	the	levels	of	estrogen	begin	to	decrease,	causing	some	women	a	variety	of	mild	to	severe	symptoms.204			Fifty	to	eighty-two	percent	of	US	women	experience	hot	flashes,	or	a	sudden	feeling	of	heat	that	may	last	seconds	to	several	minutes,	causing	flushing,	chills,	clamminess,	perspiration,	anxiety,	sleep	disturbances	(night	sweats),	and	heart	palpitations.205,206		For	87	percent	of	these	patients,	such	vasomotor	episodes	occur	daily,	and	at	least	ten	times	per	day	for	33	percent	of	patients;	the	median	duration	of	symptoms	varies	from	4	to	10	years.207		Ten	to	forty	percent	of	patients	experience	vaginal	atrophy,	vaginal	dryness,	and	urinary	tract	changes	and	infections.208		Other	symptoms	include	osteoporosis,	or	the	loss	of	bone	density	leading	to	fractures	including	those	of	the	hip	or	spine,	mood	changes,	irregular	periods,	weight	gain,	and	slowed	metabolism.209,210	To	treat	the	perimenopausal	and	menopausal	symptoms	of	some	patients,	estrogen	is	used	as	hormone	replacement	therapy	(HRT),	or	“estrogen	therapy”	(ET).211		For	those	who	have	never	had	a	hysterectomy	and	still	have	a	uterus,	progestin	is	added	to	reduce	the	risk	of	endometrial	or	uterine	cancer,	in	a	treatment	known	as	“combined	hormone	therapy”	(CHT).212,213		While	certain	symptoms	may	be	treated	with	a	local	estrogen-only	regimen,	combination	therapy	is	administered	systemically	in	the	form	of	pills	or	a	skin	patch.214	Systemic	estrogen,	with	or	without	progestin,	is	the	most	effective	proven	treatment	for	relieving	hot	flashes	and	night	sweats.215		Systemic	estrogen	therapy	has	been	shown	to	protect	against	bone	loss	and	prevent	hip	and	spine	fracture.216		Combined	therapy	may	also	help	to	reduce	the	risk	of	colon	cancer,	and	systemic	or	local	estrogen	therapy	is	effective	in	relieving	vaginal	dryness.217			However,	hormone	therapy	is	also	associated	with	an	increased	risk	for	certain	diseases	and	conditions.		Estrogen	therapy	alone	increases	the	risk	of	endometrial	or	uterine	cancer,	as	the	treatment	causes	the	lining	of	the	uterus	to	grow;	use	of	progestin	in	combination	with	estrogen	decreases	this	risk.218		Estrogen	therapy	is	also	associated	with	a	small	increased	risk	for	gallbladder	disease,	which	may	be	reduced	with	non-oral	therapy	administration.219,220		Combined	therapy	is	associated	with	a	small	increased	risk	of	heart	attack;	this	risk	is	related	to	a	patient’s	age,	when	she	begins	therapy,	and	her	other	medical	conditions.		However,	for	women	younger	than	60	who	begin	combined	therapy	within	10	years	of	menopause,	the	combined	therapy	may	protect	against	heart	attack.221		Combined	therapy	is	also	associated	with	a	small	increased	risk	for	stroke	and	deep	vein	thrombosis	(DVT),	which	may	be	diminished	by	using	non-oral	therapy	routes.	222		Combined	hormone	therapy	is	also	associated	with	a	small	increased	risk	of	breast	cancer,	and	is	not	recommended	as	a	first-line	treatment	for	patients	with	a	history	of	hormone-sensitive	breast	cancer.223	Evidence	now	exists	to	support	certain	non-hormonal	treatment	of	menopausal	symptoms,	including	selective	serotonin	reuptake	inhibitors	and	selective	serotonin/norepinephrine	reuptake	
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inhibitors	(SSRI	and	SNRI,	types	of	anti-depressants),224	clonidine/Catapres	(a	drug	used	to	lower	blood	pressure),225	and	gabapentin/Neurotin	(a	drug	approved	to	treat	seizures)226	for	treatment	of	hot	flashes.227		However,	the	only	FDA-approved	non-hormonal	therapies	include	paroxetine	for	vasomotor	symptoms	(hot	flashes)228	and	ospemifene	for	dyspareunia	(difficult	intercourse),229	both	approved	in	2013.		Herbal	treatments,	estriol,	and	bio-identical	hormones	are	not	currently	FDA-approved	for	the	treatment	of	menopausal	symptoms.230	The	use	of	HRT	became	very	controversial	after	release	of	the	findings	of	the	landmark	1998	Women’s	Health	Initiative	(WHI)	clinical	trials.		These	studies,	conducted	by	the	National	Heart,	Lung	&	Blood	Institute,	focused	on	the	prevention	of	heart	disease,	breast	and	colorectal	cancer,	and	osteoporosis	in	postmenopausal	women	through	treatment	with	hormone	therapy,	dietary	patterns,	and	calcium/vitamin	D	supplements.231		Additional	similar	studies	included	the	collaborative	reanalysis	(CR)	and	the	Million	Women	Study	(MWS).		Researchers	from	these	studies	concluded	that,	while	hormone	therapy	reduced	risks	of	colorectal	cancer	and	fractures	from	osteoporosis,	it	potentially	increased	risks	for	coronary	heart	disease,	breast	cancer,	venous	thromboembolism,	stroke,	cholecystitis,	dementia,	and	lower	global	cognitive	function.232		Critics	of	the	studies’	designs	and	generalizability	questioned	these	results,233,234,235,236,237	yet	many	patients	and	clinicians	failed	to	differentiate	when	comparing	the	risk	and	rewards	of	using	HRT	for	treatment	of	menopausal	symptoms	versus	its	use	for	chronic	disease	prevention	in	postmenopausal	women.		This	confusion	led	many	clinicians	and	patients	to	abruptly	end	HRT,	which	caused	“a	significant	and	sudden	reduction	in	quality	of	life,”	and	led	patients	to	seek	alternative	treatments	that	had	not	been	studied	for	safety	and	efficacy	when	used	for	menopausal	symptoms.238	The	current	recommendations	of	the	American	College	of	Obstetricians	and	Gynecologists	related	to	the	treatment	of	menopausal	vasomotor	and	vaginal	symptoms	direct	patients	and	providers	to	discuss	the	individual’s	benefits	and	risks	from	HRT.		In	general,	patients	should	use	the	lowest	effective	dose	for	the	shortest	time	possible	to	treat	menopausal	symptoms,	and	should	be	reevaluated	yearly	to	continuously	assess	benefits	and	risks	of	treatment.		Additionally,	the	treatment	guidelines	published	by	the	Endocrine	Society	recommend	screening	for	breast	cancer	and	cardiovascular	risk	before	initiating	HRT.239	Researchers	who	retrospectively	examined	the	impact	of	the	WHI	results	on	HRT	use	concluded:	[Q]uestions	about	the	long-term	health	consequences	of	HRT	remain.	The	women	in	the	WHI	were	older	and	taking	higher	doses	of	estrogen	than	women	using	HRT	today.	In	addition,	a	number	of	other	hormonal	options	are	available,	yet	their	comparative	risks	and	benefits	are	unknown.	These	include	different	types	of	hormones	—	conjugated	and	synthetic	estrogens,	phytoestrogens,	synthetic	progestin,	and	natural	progesterone	—	and	modes	of	delivery	—	oral	tablets,	transdermal	patches,	local	creams,	and	intrauterine	devices.	Without	further	study,	deciding	on	the	best	treatment	plan	will	continue	to	involve	an	amount	of	guesswork.240	
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Current	guidelines	explicitly	recommend	against	the	use	of	HRT	to	prevent	postmenopausal	chronic	conditions,	including	coronary	heart	disease,241	breast	cancer,	or	dementia.242		The	USPSTF	recommends	against	the	use	of	HRT	only	when	used	for	the	prevention	of	chronic	medical	conditions,	stating:	This	recommendation	applies	only	to	postmenopausal	women	who	are	considering	hormone	therapy	for	the	primary	prevention	of	chronic	medical	conditions.	This	is	not	a	recommendation	about	the	use	of	hormone	therapy	to	treat	menopausal	symptoms,	such	as	hot	flashes	or	vaginal	dryness;	the	USPSTF	did	not	review	the	evidence	related	to	this	possible	indication	because	it	falls	outside	of	the	mission	and	scope	of	the	USPSTF.	This	recommendation	also	does	not	apply	to	women	younger	than	50	years	who	have	had	surgical	menopause.243	Estimate	of	the	cost	of	the	mandate	Regulations	issued	pursuant	to	the	ACA	(45	CFR	156.122)	require	EHBs	to	include	at	least	one	drug	in	each	USP	category	and/or	class.		The	effect	of	this	regulation	is	to	require	carriers	to	include	an	estrogen/progestin	in	their	formularies,	although	the	regulations	do	not	address	HRT	directly.		This	analysis	will	not	address	the	argument	that,	by	requiring	carriers	to	include	the	drugs	in	their	formularies,	the	federal	regulation	also	requires	them	to	pay	for	every	FDA-approved	use	of	the	drug;	i.e.,	this	analysis	will	not	assume	the	regulation	requires	carriers	to	pay	claims	for	those	drugs	specifically	for	treating	symptoms	of	menopause	in	peri-and	post-menopausal	women.	RDC	for	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	for	specific	hormone	replacement	therapy	procedures	and	pharmaceuticals	as	well	as	Evaluation	and	Management	(E&M)	procedures	with	a	diagnosis	(in	any	of	the	top	five	diagnosis	columns)	associated	with	menopause-related	hormone	regulation.		The	estimated	PMPM	RDC	paid	claim	amount	was	$0.41,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.46	(or	0.11	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.04	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.03	PMPM,	or	0.01	percent	of	Commonwealth	premium.		Table	10	below	displays	a	summary	of	these	results	and	related	statistics.	
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estimated	10.9	percent	of	women	age	15	to	44	have	an	impaired	ability	to	get	pregnant,	or	to	carry	a	baby	to	term	(impaired	fecundity).283		Between	2006	and	2010,	17	percent	of	women	age	25	to	44	or	their	partners	had	ever	used	infertility	services,	a	decrease	from	the	1995	level	of	20	percent.284	Research	shows	that	the	causes	of	infertility	are	approximately	evenly	divided	between	conditions	affecting	the	woman,	conditions	affecting	the	man,	and	unknown	causes.285		A	large	number	of	specific	conditions	are	described	within	those	categories.		For	women,	the	most	common	cause	is	problems	with	ovulation,	but	many	other	physical,	genetic,	or	environmental	causes	exist.286		For	men,	the	most	common	causes	of	infertility	are	problems	with	sperm	(production,	function,	or	delivery),	behavior	and	lifestyle	factors,	and	environmental	exposures.287	A	large	number	of	treatments	are	available	for	infertility,	and	choosing	among	them	depends	on	a	variety	of	factors,	including:	the	age	and	health	of	the	parents;	the	causes,	severity	and	duration	of	infertility;	side	effects;	and	treatment	preferences.288		Generally,	however,	treatments	can	be	categorized	as	behavioral	changes,	medication,	surgery,	intrauterine	insemination,	or	assisted	reproduction	techniques	(ART).289,290		Medications	are	most	often	used	either	to	induce	ovulation,	or	for	“controlled	ovarian	hyperstimulation”	(COH),	where	follicles	are	stimulated	to	grow,	mature,	and	ovulate.291		This	can	then	be	followed	by	artificial	insemination	or	intrauterine	insemination	if	necessary.		COH	is	also	part	of	ART,	which	are	more	complex	and	invasive	techniques	in	which	eggs	are	manipulated	and	fertilized	outside	of	the	body.		Multiple	fertilized	eggs	are	then	returned	to	a	uterus	for	implantation,	or	are	frozen	for	later	use.		Medication	or	surgery	therapies	are	used	in	85	to	90	percent	of	treated	infertility	cases;	in-vitro	fertilization	(IVF)	and	other	ART	“account	for	less	than	3	[percent]	of	infertility	services.”292	The	effectiveness	of	infertility	treatment	is	difficult	to	summarize	as	the	factors	leading	to	their	use	vary	for	each	patient.		Likewise,	many	treatments	have	not	been	evaluated	through	high-quality	studies,	and	the	definition	of	successful	treatment	is	not	standard.293,294		One	study	summarized,	“there	is	little	convincing	evidence	on	which	to	base	treatment	strategies	for	the	majority	of	infertile	couples.		More	high-quality	data	on	the	relative	superiority	of	each	treatment	option,	and	associated	adverse	events,	are	needed.”295		Testing	and	treatment	practices	of	infertility	specialists	continue	to	vary	widely	and	evolve,	while	the	age	of	couples	seeking	treatment	continues	to	rise.296	One	large	study	reviewed	research	findings	regarding	ovulation	induction,	COH	and	in-vitro	fertilization,	and	analyzed	short-term	outcomes	of	pregnancy,	live	birth,	multiple	gestation,	and	complications,	as	well	as	long-term	outcomes	of	pregnancy	and	post-pregnancy	complications	for	mothers	and	children.297		The	authors	found	that	high-quality	evidence	was	lacking	in	the	majority	of	the	studies	to	support	the	choice	of	specific	interventions.298		However,	there	was	evidence	that	pregnancy	and	live	birth	rates	were	improved	with	application	of	certain	specific	techniques.299		Other	studies	have	found	that	ART	treatments,	most	frequently	IVF	and	intracytoplasmic	sperm	injection	(ICSI),300	result	in	“reasonably	high	pregnancy	rates;”301	this	success	is	prompting	more	patients	to	seek	ART	treatments	sooner	for	their	infertility.302			However,	major	risks	are	associated	with	ART,	most	notably	multi-fetal	and	especially	higher-order	(triplets	or	more)	gestations.		More	than	30	percent	of	pregnancies	resulting	from	ART	are	twins	or	higher-order	multiple	gestations;303	the	complications	of	multiple	gestations	are	well-documented.		
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Fresh	embryos	from	non-donor	eggs:	Percentage	of	cycles	resulting	in	live	births	
Singleton		 28.0	 23.1	 17.5	 10.0	 4.0	 1.6	
Triplets	or	more	 0.5	 0.2	 0.2	 0.1	 0.0	 0.0	
All		 40.5	 31.3	 22.2	 11.7	 4.5	 1.8	
	
Frozen	embryos	from	non-donor	eggs:	Percentage	of	transfers	resulting	in	live	births	
Singleton		 31.9	 31.2	 26.7	 22.0	 15.3	 10.1	
Triplets	or	more	 0.4	 0.2	 0.2	 0.1	 0.1	 0.0	


























Paid	PMPM 3.96$																 3.57$																 0.48$																
Paid	PMPM	With	Admin 4.44$																 4.01$																 0.54$																











compass Health Analytics 41 December 2016 
Effect	of	the	mandate	on	health	Phenylketonuria	(PKU)	is	a	rare	metabolic	disorder	caused	by	a	defect	in	the	gene	that	helps	to	create	the	liver	enzyme	needed	to	break	down	the	amino	acid	phenylalanine	(Phe),	which	then	builds	up	in	the	blood	and	other	tissues.315,316,317		Untreated,	PKU	can	lead	to	microencephaly,	mental	retardation,	seizures,	congenital	heart	disease,	and	other	significant	physical,	mental,	behavioral,	and	developmental	disorders.318		Women	with	untreated	PKU	during	pregnancy	may	bear	children	prematurely,	or	who	suffer	from	birth	defects.319		The	prevalence	of	PKU	is	approximately	1	in	13,500	to	19,000	births.320	In	2012,	the	National	Institutes	of	Health	sponsored	a	PKU	Scientific	Review	Conference	to	address	new	research	and	outstanding	questions	regarding	the	management	of	PKU,	while	the	Agency	for	Healthcare	Research	and	Quality	(AHRQ)	Evidence-based	Practice	Center	(EPC)	conducted	an	evidence	review	of	the	comparative	effectiveness	of	PKU	treatment,	including	diet	and	pharmacological	interventions.321,322		The	result	of	these	collaborative	efforts	included	recognition	of	the	effectiveness	of	strict	dietary	control	to	lower	levels	of	the	Phe	amino	acid	in	the	body,	before	pregnancy	in	women	and	after	birth	for	children	with	PKU.323,324	The	low-Phe	diet	includes	medical	food	and	formulas,	minimal	animal	products,	and	fruits	and	vegetables	high	in	carbohydrates,	and	low	in	saturated	and	unsaturated	fat	and	cholesterol.325		This	restricted	diet	may	create	nutritional	deficits	in	some	patients,	especially	for	natural	proteins;	many	patients	take	amino	acid	supplements	as	well	as	other	vitamins	and	minerals	to	compensate	for	these	deficiencies.326		In	2007,	the	use	of	sapropterin	dihydrochloride	(Kuvan)	was	approved	for	the	treatment	of	PKU	for	patients	who	tolerate	and	respond	to	the	drug,	to	be	taken	in	addition	to	the	low-Phe	diet.327,328		Research	has	shown	the	drug	may	help	some	patients	to	control	Phe	concentrations	while	increasing	tolerance	of	dietary	Phe.329	To	reduce	the	risk	of	birth	defects	and	other	developmental	abnormalities,	mothers	at	risk	for	PKU	during	pregnancy	must	achieve	and	maintain	control	of	dietary	Phe,	preferably	three	months	before	conception.330,331		For	most	children	born	with	PKU	identified	through	newborn	screening	who	are	treated	early	in	life	and	can	comply	with	this	low-Phe	diet,	the	outcomes	have	shown	“remarkable	success	in	preventing	the	devastating	brain	damage	associated	with	untreated	PKU.”332		In	fact,	those	able	to	achieve	and	maintain	metabolic	control	“have	normal	health	and	development	and	can	likely	expect	a	normal	life	span.”333		However,	the	nutritional	treatment	is	difficult	to	maintain	and	complicated,	while	the	formulas	are	often	unpalatable	and	expensive.334,335		Moreover,	the	low-Phe	diet	is	not	completely	effective	for	all	patients,	as	adherence	is	difficult	and	some	patients	may	experience	neurocognitive	defects	and	progressive	cognitive	impairment	despite	therapy.336,337		For	these	reasons,	research	continues	to	explore	the	development	of	new	therapies.338,339		Overall,	however,	while	the	precise	level	of	phenylalanine	restriction	is	unclear,	research	has	shown	that	the	low-Phe	diet	is	effective	in	reducing	blood	phenylalanine	levels	and	improving	neuropsychological	outcomes	and	intelligence	quotient	for	patients	with	PKU.340,341	Estimate	of	the	cost	of	the	mandate	The	LPF	mandate	covers	low	protein	food	products	required	to	treat	infants	and	children	with	specified	metabolic	disorders	as	well	as	fetuses	of	pregnant	women	with	PKU.		Costs	of	the	mandate	
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psychological	disorders,	or	those	whose	energy	demands	cannot	be	met	with	oral	nutrition,	such	as	some	AIDS	patients.346,347		HEN	is	not	without	complications,	including	problems	with	tubes,	gastrointestinal	complications,	and	quality	of	life	impact.348		One	study	highlighted	the	very	limited	evidence	comparing	the	benefit	of	EN	compared	to	the	complications,	quality	of	life,	costs	and	cost-effectiveness.349		Research	suggests	that	indications	for	the	use	of	HEN	should	be	outcome-specific.350,351		Some	studies	have	found	that	“EN	has	been	accepted	and	implemented	despite	the	lack	of	convincing	scientific	support	of	efficacy,”	and	encouraged	providers	to	determine	the	effectiveness	of	such	therapy	by	specific	patient,	disease-state,	and	its	corresponding	research	and	evidence.352		A	recent	clinical	trial	concluded	that	while	HEN	improved	clinical	outcomes,	“[i]t	was	impossible…to	determine	precisely	which	factor	mattered	more:	the	artificial	diet	itself	or	the	introduction	of	complex	care.”353,354	In	summary,	studies	of	enteral	feeding	have	shown	that,	for	patients	whose	oral	intake	of	nutrition	is	inadequate	and	who	have	a	functional	gastrointestinal	tract,	EN	does	increase	nutritional	intake	and	thus	improve	nutritional	status;355,356	for	these	patients,	HEN	is	a	“life-sustaining	therapy.”357	Malnutrition	is	a	serious	complication	of	many	diseases,	and	enteral	feeding,	when	appropriately	prescribed	and	used,	can	minimize	complications	and	be	life-saving.358		Tube	feeding	helps	a	patient	to	increase	nutritional	intake	and	avoid	starvation	and	organ	failure,	and	serves	to	maintain	the	intestinal	tract’s	integrity	and	local	defense	barrier,	thereby	preventing	additional	digestive	deterioration	and	the	spread	of	destructive	bacteria.359		According	to	the	American	Gastroenterological	Association,	“[t]ube	feeding	should	be	considered	when	the	patient	cannot	or	will	not	eat,	the	patient	has	a	functional	gut,	and	a	method	of	access	can	be	safely	obtained.”360	Estimate	of	the	cost	of	the	mandate	The	mandate	requires	"coverage	for	nonprescription	enteral	formulas	for	home	use…which	are	medically	necessary	for	the	treatment	of	mal-absorption	caused	by	Crohn's	disease,	ulcerative	colitis,	gastro-esophageal	reflux,	gastrointestinal	motility,	chronic	intestinal	pseudo-obstruction,	and	inherited	diseases	of	amino	acids	and	organic	acids.”		Therefore,	paid	amounts	from	all	claims	with	a	procedure	code	indicating	purchase	of	such	formulas	and	a	primary	diagnosis	of	a	covered	disorder	were	summed	to	estimate	RDC.	The	estimated	PMPM	RDC	paid	claim	amount	was	$0.03,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.04	(or	0.01	percent	of	the	Commonwealth	total	premium).		Self-insured	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	expenses,	resulting	in	a	$0	lower	bound	impact	estimate,	including	administrative	loading.		Table	15	below	displays	a	summary	of	these	results	and	related	statistics.	
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As	regimens	have	developed	and	improved,	the	route	of	treatment	administration	has	continued	to	evolve.		While	scientists	increasingly	focus	on	targeted	agents,	oral	administration	is	becoming	more	common,	allowing	patients	to	take	chemotherapy	drugs	by	mouth	via	a	pill,	liquid,	or	film.369		Each	year,	a	larger	proportion	of	newly-approved	drugs	are	oral,	some	of	which	are	not	available	as	an	intravenous	equivalent.370		(To	receive	FDA	approval,	drugs	must	be	proven	through	significant	research	studies	to	be	safe	and	effective;	therefore,	as	more	oral	forms	of	treatment	have	received	FDA	approval,	they	have	been	proven	effective	for	their	labeled	conditions.371)		While	some	drugs	cannot	be	delivered	by	mouth	because	of	digestive	irritation	and	absorption	issues,	oral	delivery	has	the	potential	to	deliver	drugs	over	a	more	sustained	period	in	a	more	convenient	way,372	providing	patients	with	a	sense	of	more	control	over	their	disease	and	treatment.373		In	most	cases	with	oral	therapies,	patients	are	able	to	avoid	the	sometimes	daily	medical	visits	for	infusion,	but	in	turn	must	accept	more	individual	responsibility	for	treatment.374	While	patients	gain	convenience	and	control,	they	must	comply	strictly	with	instructions	on	when	and	how	to	take	medication,	monitor	for	complications,	appropriately	handle	and	store	medications,	and	continue	follow-up	with	their	healthcare	providers.375		With	the	shift	from	office-	to	home-based	treatment,	the	traditional	roles	of	the	patient,	oncology	treatment	professionals,	including	doctors,	nurses	and	pharmacists,	and	insurance	and	delivery	management	systems,	also	shift.376		Compliance	and	medication	errors	must	be	continuously	monitored	and	addressed	by	the	entire	team,	now	including	the	patient,	to	assure	maximum	treatment	effectiveness.377		And	with	oral	delivery,	patient	outcomes	are	also	impacted	by	food	and	drug	interactions,	which	affect	the	effectiveness	and	toxicity	of	the	drug.378,379		Research	has	found	that	patients’	shift	from	a	passive	to	a	more	active	treatment	role	has	created	a	need	to	provide	them	more	information	and	support	to	help	them	comply	with	their	regimens.380,381,382,383,384	Oral	therapies,	which	are	often	new	drugs	still	under	patent	protection,	are	often	much	more	expensive	than	intravenous	treatments.		To	the	extent	patients	are	responsible	for	the	costs	of	medication,	particularly	if	that	cost	is	very	high,	that	cost	might	affect	their	compliance	or	at	least	their	choice	of	treatment	if	infused	alternative	are	available.385		Prior	to	implementation	of	the	Massachusetts	mandate,	self-administered	drugs	would	often	have	proportionately	higher	cost	sharing	than	would	infused	drugs,	since	the	self-administered	drugs	were	typically	covered	under	a	pharmacy	benefit	while	infused	drugs	were	typically	covered	under	a	medical	benefit;	the	former	typically	has	higher	cost	sharing.	Estimate	of	the	cost	of	the	mandate	RDC	for	this	mandate	was	calculated	as	the	decrease	in	PMPM	patient	cost	sharing	(defined	as	the	difference	between	PMPM	allowed	expenses	and	PMPM	carrier-paid	expenses)	expenses	for	all	claims	reporting	a	procedure	or	NDC	code	indicating	an	orally-administered	cancer	medication	between	2012	(prior	to	implementation	of	the	law)	and	2014	(after	implementation	of	the	law).		The	lower	bound	impact	estimate	was	calculated	as	the	difference	between	the	fully-insured	cost	sharing	PMPM	and	the	self-insured	cost	sharing	PMPM	for	these	medications	between	2012	and	2014.		The	analysis	does	not	adjust	for	expected	changes	in	average	cost-sharing	for	these	products	between	the	two	years	in	the	absence	of	a	mandate;	such	an	analysis	is	outside	the	scope	of	this	study.		To	the	extent	that	average	patient	cost-sharing	for	these	products	would	have	been	higher	in	
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diabetes	and	peripheral	arterial	disease	(54	percent),	trauma	(45	percent),	and	cancer	(under	two	percent).389,390		An	estimated	2.0	million	or	more	Americans	live	with	limb	loss,	and	over	185,000	amputations	occur	annually	in	the	United	States.391			To	understand	prevalence	of	individuals	with	limb	loss	and	incidence	rates	of	new	amputations,	considering	patient	age	is	critical.		Over	64	percent	of	dysvascular	disease-related	amputations	occur	among	adults	65	and	older.392		As	the	population	ages	and	the	number	of	individuals	diagnosed	with	diseases	such	as	diabetes	continue	to	rise,	annual	new	cases	of	amputations	are	expected	to	double	by	2050.393		The	severity	of	the	conditions	that	lead	to	amputation	in	this	older	population	limits	average	life	expectancy	in	that	group.		Five-year	mortality	for	patients	whose	vascular	disease	led	to	amputations	is	almost	50	percent,	higher	than	the	same	measure	for	breast,	colon,	Hodgkin’s	lymphoma,	and	prostate	cancers.394		For	patients	who	need	a	lower	extremity	amputation	due	to	diabetes,	the	five-year	mortality	rate	is	up	to	74	percent.395,396	By	2050,	the	number	of	people	living	with	a	lost	limb,	and	thus	in	need	of	prosthetics	and	related	services,	is	estimated	to	triple.397		This	is	due	to	the	age	of	the	patients:	although	only	16	percent	of	hospital	discharges	related	to	amputation	are	due	to	trauma,	trauma	cases	account	for	approximately	45	percent	of	people	living	with	limb	loss,	two	thirds	of	whom	are	adolescents	and	adults	younger	than	45.398	In	general,	amputations	are	categorized	as	upper	limb	(arm	and	hand)	and	lower	limb	(leg	and	foot).399		Overall,	younger	patients	are	more	likely	to	suffer	from	upper	limb	loss,	and	older	patients	from	lower	limb	loss.		Lower	limb	prosthetics	have	higher	rates	of	acceptance	and	daily	use,	while	upper	limb	prosthetics	have	higher	rates	of	abandonment.400		These	findings	may	be	attributable	to	overall	intended	functions	for	each	prosthetic	type.		Lower	limb	prostheses	are	designed	to	accomplish	gross	motor	tasks,	including	weight-bearing,	balance,	ambulation,	and	provide	more	natural	cosmetic	appearance,401	functions	“well	substituted	for	by	the	prosthesis.”402		For	upper	limbs,	prosthetics	must	perform	fine	motor	tasks	and	balance,	in	addition	to	movement	and	natural	cosmetic	appearance.403		Moreover,	in	the	case	of	thumb	amputation,	the	prosthesis	must	provide	opposition.		Generally,	fine	motor	functions	are	“not	well	served	by	a	prosthetic	device.”404		Acceptance	rates	and	functionality	improve	while	abandonment	decreases	with	early	prosthetic	fittings,	which	also	decreases	risk	of	phantom	pain.405	Complications	related	to	limb	loss	include:	psycho-social	adjustment;	soft	tissue	and	muscle	atrophy;	skin	disorders,	including	increased	moisture,	blisters,	allergic	reactions,	irritation	and	breakdown;	joint	contracture;	soft	tissue	and	bone	infections;	pain	and	phantom	limb	sensations;	overuse	syndromes	in	remaining	extremities	and	proximal	joints;	and	heterotopic	ossification,	or	an	overgrowth	of	bone	instead	of	scar	tissue.	406,407,408		In	the	short-term,	prosthetic	patients	are	more	likely	to	experience	depression	and	anxiety,	as	well	as	social	discomfort	and	body-image	anxiety.409	Each	type	of	amputation	requires	a	different	prosthetic,	each	with	its	own	rate	of	effectiveness.		Generally,	the	functionality	of	the	prosthesis	is	related	to:	the	number	of	joints	preserved	and	the	length	of	the	residual	limb;410	other	orthopedic,	cardiovascular,	neuromuscular,	and	respiratory	conditions;	vascular	and	visual	problems;	and	a	patient’s	emotional	and	mental	health,	activity	
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events	such	as	brain	injuries	and	strokes.		The	specific	problems	vary	widely,	as	do	treatment	methods	and	modalities.		For	children,	“[p]rimary	speech	and	language	delay/disorder	is	a	common	developmental	difficulty	which,	if	unresolved,	can	cause	difficulties	of	both	learning	and	socialisation	lasting	into	adolescence	and	beyond.”435		In	general,	“[s]peech	and	language	therapy	aims	to	maximize	ability	to	communicate	through	speech,	gesture,	and/or	supplementary	means,	such	as	communication	aids,	and	to	enable	[patients]	to	become	independent	communicators.”436,437	Most	studies	reviewed	suggest	the	effectiveness	of	treatment	for	speech,	hearing,	and	language	disorders	in	general;	however,	one	large	systematic	review	found	that	many	of	the	conclusions	are	based	on	“’clinical	opinion’	rather	than	on	controlled	clinical	trials.”438		Many	investigators	cited	the	need	for	additional	research	to	be	conducted	using	rigorous	scientific	methodology,	and	for	the	development	of	more	consistent	standards	of	treatment	methods	and	interventions,	as	well	as	evidence-based	practice	guidelines	for	the	variety	of	conditions	requiring	speech,	hearing,	and	language	therapies.439,	440,	441,	442,	443,444,445	Estimate	of	the	cost	of	the	mandate	Regulations	on	required	benefits	for	2016	issued	pursuant	to	the	ACA	(45	CFR	§156.115(a)(5)(i))	include	in	EHBs	“habilitative	services”.		They	define	such	services	as	those	that	“help	a	person	keep,	learn,	or	improve	skills	and	functioning	for	daily	living	(habilitative	services).		Examples	include	therapy	for	a	child	who	is	not	walking	or	talking	at	the	expected	age.		These	services	may	include	physical	and	occupational	therapy,	speech-language	pathology	and	other	services	for	people	with	disabilities	in	a	variety	of	inpatient	and/or	outpatient	settings.”		But	the	specific	services	included,	and	whether	the	definitions	would	include	speech	and	audiology	services,	are	unclear	on	the	surface	and	left	to	the	states.446		For	reasons	cited	in	the	overview	of	the	methodology,	this	analysis	assumes	federal	EHB	requirements	do	not	address	state-mandated	speech	and	audiology	services.	
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the	American	Association	of	Nurse	Anesthetists,	“[i]n	some	states,	CRNAs	are	the	sole	providers	in	nearly	100	percent	of	the	rural	hospitals,”	and	are	the	primary	anesthesia	providers	in	rural	America	overall,	providing	care	in	trauma	stabilization,	surgical,	obstetrical,	and	pain	management	cases.475	As	APRNs,	CRNAs	are	required	to	complete	a	baccalaureate	degree	program	in	nursing	or	other	appropriate	field,	a	graduate	degree	program	in	nurse	anesthesia,	and	they	must	pass	a	national	certification	exam	following	graduation.476		A	CRNA	must	be	licensed	as	a	registered	nurse	(RN),	and	spend	at	least	one	year	as	an	RN	in	a	critical	care	setting.477		In	Massachusetts,	CRNAs	are	certified	to	practice	as	an	Advanced	Practice	Clinical	Nurse	in	their	specific	clinical	category.478	The	federal	Centers	for	Medicare	and	Medicaid	Services	(CMS)	currently	requires	that	CNRAs	be	supervised	by	a	physician,	unless	the	state’s	own	regulations	do	not	require	the	CRNA	to	be	supervised.479		States	may	opt-out	of	this	requirement;480	since	2001,	17	states	have	formally	opted-out.481,482		However,	there	is	significant	disagreement	in	the	number	of	remaining	states	in	which	CRNAs	may	operate	independently	without	need	for	the	opt-out	filing,	with	estimates	ranging	from	18	to	40	states;	CRNA	independence	hinges	on	the	definition	of	“physician	supervision”	in	state	regulations.483		In	2008,	the	National	Council	of	State	Boards	of	Nursing	(NCSBN)	adopted	the	Consensus	Model	for	Advanced	Practice	Registered	Nurse	(APRN)	Regulation	in	an	attempt	to	create	consistent	regulations	and	legislation	across	the	United	States.484		The	group	is	attempting	to	standardize	licensure	to	practice,	APRN	program	accreditation,	national	certification	requirements,	and	educational	requirements.485	In	Massachusetts,	CRNAs	do	not	have	independent	prescribing	authority.		Instead,	they	must	have	a	written	agreement	outlining	physician	supervision	of	their	prescriptive	practice,486,487	the	physician’s	name	must	appear	on	the	prescription,	and	prescribing	practices	are	regulated	for	CRNAs	by	both	the	state	Board	of	Registration	in	Nursing	and	the	Board	of	Medicine.488		CRNA	prescriptive	practice	is	also	limited	to	“the	immediate	perioperative	care	of	a	patient.”489		These	regulations	make	Massachusetts	the	only	New	England	state	without	full	practice	authority	for	CRNAs	(although	Maine	requires	CRNAs	to	practice	under	physician	or	dentist	supervision).490		In	a	review	of	seven	years	of	Medicare	data	analyzing	patient	safety	outcomes	for	patients	provided	anesthesia,	researchers	found	that	“the	change	in	CMS	policy	allowing	states	to	opt	out	of	the	physician	supervision	requirement	for	certified	registered	nurse	anesthetist	reimbursement	was	not	associated	with	increased	risks	to	patients.”491		Other	studies	comparing	rates	of	complications	for	obstetrical	anesthesia	between	CRNAs	and	anesthesiologists	found	no	difference	between	the	two	staffing	models.492,493		In	a	large	study	comparing	the	safety	and	effectiveness	of	non-physician	anesthetists	(NPAs)	practicing	independently,	anesthesiologists,	and	NPAs	supervised	or	directed	by	physicians,	the	researchers	found	that	“[n]o	definitive	statement	can	be	made	about	the	possible	superiority	of	one	type	of	[anesthesia]	care	[provider]	over	another.”494	
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prevention	in	addition	to	diagnosis,	treatment	and	management	of	chronic	and	acute	illness.498		More	than	80	percent	of	nurse	practitioners	are	trained	in	primary	care,	most	often	practicing	in	family,	geriatrics	and	adults,	women’s	health,	and	pediatrics.499		There	were	over	192,000	licensed	NPs	practicing	in	the	United	States	in	2014,	including	over	7,700	in	Massachusetts;500	over	900	million	visits	are	made	annually	to	NPs.501		In	Massachusetts,	an	NP	is	certified	to	practice	as	an	Advanced	Practice	Clinical	Nurse	in	a	specific	clinical	category.502	As	with	all	APNs,	NPs	must	complete	at	least	four	years	of	undergraduate	education	and	either	a	master’s,	post	master’s,	or	doctoral-level	graduate	program	for	NPs.503		Nurse	Practitioners	can	be	licensed	and	may	prescribe	medications	in	all	50	states,504,505	although	the	scope	of	practice	and	physician	oversight	requirements	may	vary	across	states.506,507		In	2008,	the	National	Council	of	State	Boards	of	Nursing	(NCSBN)	adopted	the	Consensus	Model	for	Advanced	Practice	Registered	Nurse	(APRN)	Regulation	in	an	attempt	to	create	consistent	regulations	and	legislation	across	the	United	States.508		The	group	is	attempting	to	standardize	licensure	to	practice,	APRN	program	accreditation,	national	certification	requirements,	and	educational	requirements.509	In	Massachusetts,	NPs	do	not	have	independent	prescribing	authority,	but	“must	have	a	collaborative	agreement	with	a	physician	or	a	physician's	supervision/delegation	in	order	to	prescribe	drugs.”510		NPs	must	have	a	written	agreement	in	place	outlining	physician	supervision	of	their	prescriptive	practice,511	the	physician’s	name	must	appear	on	the	prescription,	and	prescribing	practices	are	regulated	for	NPs	by	both	the	state	Board	of	Registration	in	Nursing	and	the	Board	of	Medicine.512		These	regulations	make	Massachusetts	the	only	New	England	state	without	full	practice	authority,	prompting	the	American	Academy	of	Nurse	Practitioners	to	place	it	among	the	12	“most	restrictive	of	practice	environments	in	the	nation.”513,514	In	a	review	of	articles	comparing	the	quality	and	safety	of	care	provided	by	NPs	to	that	provided	medical	doctors	(MDs),	researchers	found	that	outcomes	were	comparable	or	better	for	all	11	outcomes	reviewed,	including	strong	evidence	that	rates	were	similar	for	patient	satisfaction	with	provider/care,		functional	status,	numbers	of	unexpected	ED	visits,	hospitalization	rates,	patient	blood	pressure,	blood	glucose,	serum	lipids,	patient	outcomes	for	mortality,	and	self-reported	perceived	health	status.515		Another	review	of	randomized	controlled	trials	found	that	while	longer	term	outcomes	should	be	assessed	through	additional	studies,	“there	were	few	differences	in	primary	care	provided	by	APNs	and	physicians;	for	some	measures	APN	care	was	superior.”516		Another	review	found	that	ANPs	could	help	improve	primary	care	of	patients	with	chronic	disease,	and	that	independent	specialized	nurses:	…could	achieve	health	outcomes	that	were	similar	to	those	of	doctors,		reduce	hospital	visits	and	improve	certain	patient	outcomes	related	to	diabetes,	coronary	artery	disease,	or	heart	failure.		Patients	who	had	nurse-led	care	were	more	satisfied	and	tended	to	receive	more	tests	and	medications.	It	is	unclear	whether	specialized	nurses	improve	quality	of	life	or	doctor	workload.517	Estimate	of	the	cost	of	the	mandate	The	nurse	practitioner	(NP)	mandate	requires	plans	to	cover	services	of	nurse	practitioners	(NPs)	when	the	same	services	are	reimbursed	when	performed	by	any	other	practitioner	and	are	within	the	lawful	scope	of	practice	of	nurse	practitioners.		M.G.L.	c.	176R	allows	NPs	to	serve	as	Primary	Care	Physicians	and	prohibits	NPs	from	being	subject	to	reduced	coverage	limits.		The	RDC	of	this	
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classroom,	laboratory,	and	clinical	experience.545		For	licensure	in	Massachusetts,	graduates	of	a	chiropractic	college	must	pass	parts	I,	II,	III,	and	IV	and	the	physiotherapy	section	of	examinations	administered	by	the	National	Board	of	Chiropractic	Examiners,	as	well	as	the	Massachusetts	jurisprudence	examination	administered	by	the	state	Board	of	Registration	of	Chiropractors.546		Massachusetts	also	requires	chiropractors	to	complete	12	hours	of	continuing	education	annually	to	maintain	and	renew	licensure.547	Licensed	chiropractors	are	recognized	by	Medicare	for	payment	as	a	physician	only	for	manual	spinal	manipulation	treatment	of	spinal	subluxation.548		Chiropractors	are	not	eligible	to	order	and/or	refer	for	Part	B	and	DMEPOS	(durable	medical	equipment,	prosthetics,	orthotics,	and	supplies)	Medicare	beneficiaries,549	but	may	act	as	a	supplier	of	durable	medical	equipment.550	Limited	research	is	available	comparing	outcomes	among	provider	types	who	perform	spinal	manipulation	(e.g.	chiropractor	versus	physician).		However,	one	large	meta-analysis	that	reviewed	the	results	of	39	randomized-controlled	trials	concluded	that	“[t]he	evidence	is	insufficient	to	conclude	that	benefits	of	manipulation	vary	according	to	the	profession	of	the	manipulator	(chiropractor	vs.	other	clinician	trained	in	manipulation).”551		Another	study	found	that,	when	comparing	orthopedic	surgeons,	primary	care	providers,	and	chiropractors,	the	time	to	functional	recovery,	complete	recovery,	and	return	to	work	after	treatment	for	lower	back	pain	was	similar	between	all	three	provider	types.552		The	same	study	found	that	costs	were	lowest	for	primary	care	providers,	and	patient	satisfaction	highest	for	chiropractors.553		A	more	recent	article	examining	the	costs	of	care	between	chiropractors	and	other	providers	was	equivocal	in	its	conclusions	and	called	for	additional	research.554	Estimate	of	the	cost	of	the	mandate	The	chiropractor	provider	mandate,	c.	175	§	108D,	requires	a	payer	to	pay	for	chiropractic	services	whether	they	are	performed	by	a	physician	or	chiropractor,	and	c.	176B	§	7	statute	prohibits	a	Medical	Services	Corporation	from	discriminating	against	chiropractors	in	providing	chiropractic	services.		Note	that	there	are	both	chiropractic	service	and	chiropractor	(provider-based)	mandates.		The	chiropractors	provide	both	chiropractic	services	and	non-chiropractic	services,	and	chiropractic	services	are	provided	by	both	chiropractors	and	other	providers.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	chiropractor	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.91,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$1.02	(or	0.07	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.15	lower	than	fully-insured	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.10	PMPM,	or	0.01	percent	of	Commonwealth	premium.		Table	24	below	displays	a	summary	of	these	results	and	related	statistics.	
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Optometrists	The	optometrist	mandate	requires	coverage	for	services	of	optometrists	when	those	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	within	the	lawful	scope	of	practice	of	optometrists.570	Effect	of	the	mandate	on	health	Optometrists,	or	doctors	of	optometry,	are	independent	health	care	professionals	who	diagnose	and	treat	eye	and	visual	system	diseases	and	disorders.571		Educational	requirements	for	optometrists	include	four	years	of	undergraduate	education	and	four	years	of	graduate	study	at	a	college	of	optometry.572		To	practice,	optometrists	must	obtain	state	licensure,	requiring	them	to	pass	a	set	of	national	examinations	administered	by	the	National	Board	of	Examiners	in	Optometry	(NBEO).		In	Massachusetts,	these	include	five	tests,	including	applied	basic	science,	patient	assessment	and	management	(PAM),	clinical	skills,	treatment	and	management	of	ocular	disease	(TMOD),	and	state	jurisprudence.573,574		Passing	these	examinations	also	grants	optometrists	certification	to	use	or	prescribe	diagnostic	pharmaceutical	agents	(DPA)	and	therapeutic	pharmaceutical	agents	(TPA).575		Licenses	must	be	renewed	annually576	and	must	include	evidence	of	continuing	education.577	Medicare	considers	optometrists	to	be	physicians	“with	respect	to	all	services	the	optometrist	is	authorized	to	perform	under	State	law	or	regulation.”578		This	review	found	no	published	studies	quantifying	the	efficacy	of	the	work	of	optometrists	specifically,	comparing	the	relative	quality	of	services	provided	by	optometrists	with	differing	amounts	of	education	or	training,	or	comparing	the	relative	quality	of	services		provided	by	optometrists	to	services	provided	by	other	provider	types.	The	ACA	requires	non-grandfathered	health	plans	in	the	individual	and	small	group	markets	to	cover	essential	health	benefits	(EHBs)	in	ten	categories	of	service	or	items.579		One	EHB	category,	pediatric	services,	includes	coverage	for	oral	and	vision	care	for	children.		(For	plans	effective	in	2017,	pediatric	vision	care	is	provided	through	a	supplementary	plan	under	the	Federal	Vision	Insurance	Program	(FEDVIP),	and	covers	routine	eye	exams	and	eyeglasses	for	children.580,581)		However,	while	coverage	for	pediatric	vision	services	is	required	as	an	EHB,	coverage	for	optometrists	per	se	is	not	required.582		Moreover,	routine,	non-pediatric	eye	exam	services	are	excluded	from	EHBs,	even	though	an	EHB	benchmark	plan	may	cover	them.583		Therefore,	the	ACA	and	its	EHB	requirements	do	not	affect	the	marginal	cost	of	this	mandate.	Estimate	of	the	cost	of	the	mandate	The	optometrist	mandate	requires	coverage	for	services	of	optometrists	when	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	are	within	the	lawful	scope	of	practice	of	optometrists.		The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	an	optometrist	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.71,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.80	(or	0.06	percent	of	the	Commonwealth	total	premium).		Self-insured	PMPM	allowed	medical	expenses	for	these	services	were	found	to	be	higher	than	fully-insured	allowed	medical	costs,	resulting	in	a	lower	
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B	and	Durable	Medical	Equipment,	Prosthetics,	Orthotics	and	Supplies	(DMEPOS)	Medicare	beneficiaries.594		Further,	podiatrists	may	order	and	refer	for	Medicare	Part	A	Home	Health	Agency	(HHA)	beneficiary	services,	the	only	provider	type	besides	doctors	of	medicine	and	osteopathy	permitted	to	do	so.595	While	no	evidence	was	found	comparing	the	effectiveness	of	podiatric	care	provided	by	podiatrists	to	that	provided	by	nurses,	allied	health	professionals,	or	non-specialist	physicians,	some	evidence	exists	that	interdisciplinary	foot	care	including	podiatric	care	had	a	positive	impact	on	outcomes	for	patients	with	diabetes,	including	reductions	in	urgent	surgeries,	below-knee	amputation	rates,	major	amputations,	recurrence	of	foot	ulcers,	and	death	in	patients	with	diabetic	lower-extremity	ulcerations.596,597,598,599		Other	studies	have	found	that	for	patients	waiting	for	an	evaluation	by	an	orthopedic	surgeon,	podiatrists	can	provide	appropriate	triage	service,	resulting	in	more	timely	provision	of	non-surgical	care	and	better	targeted	use	of	orthopedic	surgical	resources.600,601	This	review	found	no	published	studies	quantifying	the	efficacy	of	the	work	of	podiatrists	specifically	(noting	the	distinction	between	podiatric	care	and	care	by	podiatrists),	comparing	the	relative	quality	of	services	provided	by	podiatrists	with	differing	amounts	of	education	or	training,	or	comparing	the	relative	quality	of	podiatrists	services	against	services	provided	by	other	provider	types.	Estimate	of	the	cost	of	the	mandate	The	podiatrist	mandate	requires	coverage	for	services	of	podiatrists	when	services	are	reimbursed	when	performed	by	medical	or	osteopathic	physicians	and	are	within	the	lawful	scope	of	practice	of	podiatrists.	The	RDC	of	this	mandate	was	calculated	as	the	sum	of	paid	amounts	from	all	claims	with	a	podiatrist	provider	type	indicator.		The	estimated	RDC	PMPM	paid	claim	amount	was	$0.58,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$0.65	(or	0.15	percent	of	the	Commonwealth	total	premium).		Per	member	per	month	self-insured	allowed	expenses	for	this	mandate	were	found	to	be	$0.04	lower	than	fully-insured	and	GIC	PMPM	allowed	expenses,	resulting	in	a	lower	bound	expense	estimate,	including	administrative	loading,	of	$0.03	PMPM,	or	0.01	percent	of	Commonwealth	premium.	Table	27	below	displays	a	summary	of	these	results	and	related	statistics.	
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Phase	0	trials	are	also	possible,	in	which	patients	face	lower	risk	but	will	not	benefit	from	the	trial;	these	are	used	to	study	how	the	cancer,	body,	and	treatment	interact,	and	are	intended	to	hasten	and	streamline	the	approval	process.650	The	National	Cancer	Institute	cites	several	possible	benefits	of	participation	in	clinical	trials,	including	access	to	new	treatment,	close	monitoring	by	research	staff,	and	the	opportunity	to	help	future	patients.651		Trial	participants	who	are	randomized	into	control	groups	receive	the	best	known	standard	treatment,	while	those	in	the	test	groups	receive	the	new	treatment	intended	to	improve	upon	the	current	standard.652		The	American	Cancer	Society	(ACS)	also	points	out	that	participation	empowers	patients	to	actively	decide	their	cancer	treatment,	and	provides	an	opportunity	to	help	others	and	advance	research.653		Participation	drawbacks	may	be	that	the	new	treatment	is	not	as	effective	for	an	individual	as	the	current	standard,	or	may	cause	different	or	more	severe	side	effects	than	the	standard	treatment	protocol;	likewise,	clinical	trials	also	may	require	more	testing	or	clinical	appointments	than	would	standard	treatment.654	A	2013	study	on	public	and	patient	perspectives	of	clinical	trials	found	that	87	percent	of	respondents	were	“somewhat	willing”	or	“very	willing”	to	participate	in	clinical	trials.655		Yet	ACS	reports	that	the	biggest	barrier	to	the	completion	of	trials	is	that	fewer	than	5	percent	of	adults	participate	in	them,	with	the	most	common	reason	being	that	the	patient	did	not	know	the	studies	were	an	option	for	them.656		Of	patients	aware	of	their	eligibility,	only	25	percent	reported	participating.657		Participants	do	report	a	high	rate	of	satisfaction,	especially	with	the	quality	of	their	care;	over	75	percent	report	that	they	would	recommend	participation	to	others.658		Approximately	60	percent	of	children	under	age	15	participate,	and	this	has	been	credited	with	the	dramatic	increase	in	childhood	cancer	survival	rates	in	the	past	few	years.659	Discussion	of	the	cost	of	the	mandate	The	clinical	trials	for	treatment	of	cancer	mandate	requires	coverage	for	patient	care	services	for	patients	enrolled	in	a	qualified	clinical	trial	to	the	same	extent	as	the	services	would	be	covered	if	the	patient	was	not	receiving	care	in	a	qualified	clinical	trial.		A	qualified	clinical	trial	must	be	cancer-related	and	must	meet	other	criteria	set	forth	in	the	law.	Detailed	data	do	not	exist	to	specifically	identify	costs	associated	with	clinical	trials	for	the	treatment	of	cancer,	but	information	is	available	to	aid	in	its	estimation.		One	study	estimates	that	the	costs	of	clinical	trials	range	from	10	percent	lower	to	23	percent	higher	compared	to	standard	medical	care.660		Compass	obtained	2013	U.S.	cancer	prevalence	rates	by	10-year	age	band661	and	applied	these	rates	to	a	U.S.	Census	Bureau	estimate	of	Massachusetts	population	by	single	year	of	age	on	July	1,	2014,662	yielding	an	approximate	count	of	people	aged	0-59	in	Massachusetts	living	with	cancer	in	2014	of	74,160.		An	additional	70,062	cancer	patients	were	aged	60-69.		The	Census	data	on	Massachusetts	population	by	single	year	of	age	indicate	that	the	proportion	of	the	estimated	2014	Massachusetts	population	aged	60-69	who	were	aged	60-64	versus	60-69	was	55.1	percent.		Applying	this	proportion	to	the	estimated	Massachusetts	cancer	cases	in	the	age	60-69	age	group	and	adding	the	result	to	the	cases	in	the	population	aged	0-59	yields	a	2014	estimate	of	112,740	cancer	patients	aged	0-64	in	Massachusetts	in	2014.		However,	Massachusetts	has	a	higher	overall	incidence	rate	for	cancers	versus	the	nation	as	a	whole.		While	the	national	figure	for	2008-
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xxv	 1.31	 0.05	 0.05	
Sterilization	surgery	for	men	 3,084	 8.2	 0.10	 0.15	
Sterilization	Surgery	for	Women,	Surgical	Implant	
(Transabdominal	Surgical	Sterilization)	 9,443	 25.1	 0.5	(tubal	only)	 0.5	(tubal	only)																																									 																					
xxv	User	number	combines	permanent	sterilization	implant	and	removable	implantable	rod.	
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Shot/injection	 1,697	 4.5	 0.2	 6	
Oral	contraceptives/	combined	pill,	progestin	only	
and	extended/continuous	use	 9,720	 25.9	 0.3	 9	
Patch	 217	 0.6	 0.3	 9	







Male	condom	 5,739	 15.3	 2	 18	
Female	condom	 N/A	 N/A	 5	 21	







Withdrawal	 1,817	 4.8	 4	 22	
Fertility	awareness-basedxxviii	 509	 1.4	 0.4-5	 24	
No	method,	at-risk	of	unintended	pregnancy	 4,175	 N/A		 85	 85	
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approved	by	the	Food	and	Drug	Administration	(FDA),	including	sterilization	procedures,	implanted	devices,	barrier	and	hormonal	methods,	emergency	contraception,	and	education	and	counseling;	over-the-counter	contraception,	drugs	to	induce	abortions	and	sterilization	surgery	for	men	are	not	included	in	this	benefit.710		Health	plans	sponsored	by	certain	exempt	religious	organizations	may	not	be	covered	and	may	require	out-of-pocket	payment.711		Some	non-profit	religious	organizations	that	certify	religious	objections	do	not	have	to	contract,	arrange,	pay,	or	refer	for	contraceptive	coverage;	for	these	types	of	organizations,	insurers	or	third	party	administrators	may	make	separate	payments	for	contraceptive	services	to	in-network	providers	without	patient	cost-sharing.712 Estimate	of	the	cost	of	the	mandate	The	contraceptive	services	mandate	provides	coverage	for	outpatient	contraceptive	services	(consultations,	exams,	procedures,	etc.)	to	the	same	extent	as	other	outpatient	services	and	for	prescription	contraceptive	drugs	and	devices	under	the	same	terms	and	conditions	as	other	prescription	drugs	and	devices.	The	mandate	provides	exclusions	for	church-affiliated	employers.	The	federal	ACA	requires	contraception	coverage	as	an	essential	health	benefit	(EHB),	and,	in	addition	to	requiring	all	of	the	benefits	of	the	state	mandate,	requires	all	compliant	plans	to	cover	at	least	one	product	from	each	of	the	FDA’s	18	approved	contraception	methods	at	zero	cost-sharing.		Therefore,	this	analysis	assumes	the	Massachusetts	contraceptive	mandate	to	be	redundant	to	and	superseded	by	the	federal	ACA;	the	marginal	cost	of	the	state	mandate	is	therefore	zero.		The	contraception	provisions	of	the	ACA	were	required	in	all	new	health	insurance	plans	in	effect	on	or	after	August	1,	2012;	accordingly,	the	Massachusetts	contraception	mandate	was	treated	as	a	potential	marginal	cost	mandate	in	the	first	two	comprehensive	reviews.	Required	direct	costs	(RDCs)	of	this	mandate	were	determined	to	consist	of	paid	amounts	from	all	claims	for	female	members	for	outpatient	contraceptive	procedures	and	consultations	(IUD	insertion,	etc.),	all	claims	for	evaluation	and	management	(identified	by	the	evaluation	and	management,	or	E&M,	CPT4	codes)	with	a	contraception-related	diagnosis,	and	all	pharmacy	claims	for	contraceptive	drugs	and	devices	for	the	target	population.		The	estimated	RDC	PMPM	paid	claim	amount	for	the	calendar	year	2014	study	period	was	$3.32,	with	a	total	PMPM	cost,	after	administrative	loading,	of	$3.73	(or	0.86	percent	of	the	Commonwealth	total	premium).		Table	32	below	displays	a	summary	of	these	results	and	related	statistics.	
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percent	of	certain	types	of	oropharyngeal	cancers,	and	40	percent	of	vaginal,	vulvar,	and	penile	cancers.723		This	new	understanding	of	the	causes	of	these	cancers	has	led	to	a	shift	from	a	strategy	mostly	focused	on	screening	for	pre-cancers	and	cancers,	to	approaches	that	include	vaccination	against	HPV	to	prevent	infection,	as	well	as	screening	not	only	for	precancers	and	cancers,	but	also	HPV	itself.			Initial	infection	with	HPV	is	common	in	young	women	within	their	first	decade	of	sexual	activity.724		However,	less	than	10	percent	of	these	infections	persist	and,	relatively	slowly,	become	precancer,	most	often	between	5	and	10	years	after	initial	infection.725		From	these,	a	minority	of	cases	progress	to	invasive	cancer;	this	also	most	often	takes	many	years	or	decades,	with	the	risk	highest	in	women	35	to	55	years	old.726	Given	these	statistics,	agreement	is	near-universal	on	the	benefits	of	cytological	screening	for	women,	and	many	U.S.	government	agencies	and	medical	societies	now	agree	on	a	single	set	of	recommendations	regarding	testing	methods	and	intervals	released	in	March	2012.		These	recommendations	call	for	less-frequent	screening,	as	researchers	have	found	that:		[S]creening…	more	often	than	every	3	years	confers	little	additional	benefit,	with	large	increases	in	harms,	including	additional	procedures	and	assessment	and	treatment	of	transient	lesions.		Treatment	of	lesions	that	would	otherwise	resolve	on	their	own	is	harmful	because	it	can	lead	to	procedures	with	unwanted	side	effects,	including	the	potential	for	cervical	incompetence	and	preterm	labor.		Similarly,	the	frequency	of	HPV	testing	with	cytology	should	not	be	more	often	than	every	5	years	in	order	to	maintain	a	reasonable	balance	of	benefits	and	harms	similar	to	that	seen	with	cytology	alone	every	3	years.727	The	cytological	screening	mandate	in	Massachusetts	requires	coverage	for	screening	annually	for	women	18	years	and	older,	a	frequency	greater	than	that	in	the	current	guidelines.	The	USPSTF	currently	gives	the	recommendations	for	women	age	21	to	29	and	30	to	64	grades	of	“A”.		Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).728,729		However,	the	USPSTF	recently	released	its	“Final	Research	Plan	for	Cervical	Cancer	Screening”,	indicating	it	will	again	conduct	a	systematic	review	of	research	to	form	the	basis	of	an	updated	recommendation.730	
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Infants	received	hearing	screening	before	age	1	month	 80.1%	 91.7%	 14.5%	
Infants	received	recommended	diagnostic	follow-up	before	
age	3	months	 51.5%	 69.2%	 34.4%	
Infants	with	hearing	loss	enrolled	in	early	intervention	
before	age	6	months	 57.0%	 62.1%	 8.9%	
	The	USPSTF	currently	gives	a	“B”	rating	to	screening	for	hearing	loss	in	all	newborns,758	although	the	specific	recommendation	has	been	designated	“Inactive”.759		Under	the	ACA,	non-grandfathered	health	insurance	plans	must	fully	cover	the	costs	of	recommended	preventive	services	graded	“A”	or	“B”	without	patient	cost	sharing	(no	deductibles,	coinsurances	or	copayments).760,761	Discussion	of	the	cost	of	the	mandate		The	hearing	screening	for	newborns	mandate	requires	coverage	for	newborn	hearing	screening	tests.		The	cost	of	the	universal	newborn	hearing	screening	is	based	upon	the	number	of	newborns	in	the	state	who	were	tested	in	2014.		The	U.S.	Centers	for	Disease	Control	and	Prevention	(CDC)	reports	that	71,573	newborns	were	tested	under	the	program	in	2013.762		Applying	the	statewide	74.7	percent	private	health	insurance	rate	to	the	total	tested	newborns	and	the	49.1	percent	factor	representing	the	proportion	of	individuals	covered	by	Massachusetts-licensed	fully-insured	commercial	health	insurance	to	that	result	yields	an	estimated	26,225	fully-insured	and	GIC	
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quality	of	life	often	deteriorates	until	death.766		Despite	these	difficulties,	however,	some	studies	have	shown	hospice	care	to	be	associated	with	a	relatively	high	and	stable	quality	of	life,767	improved	pain	control,	decreased	hospitalizations,	and	decreased	tube	feedings	for	terminal	nursing	home	patients,768	improved	quality	of	death,769	and	a	reduction	in	mortality	for	the	widowed	spouse.770		A	Cochrane	review	found	that	home-based	hospice	care	increases	the	number	of	patients	who	die	at	home	versus	in	the	hospital,	which	is	more	in	line	with	their	personal	preferences.771		Two	oft-cited	studies	found	that	“for	certain	well-defined	terminally	ill	populations,	among	the	patients	who	died,	patients	who	choose	hospice	care	live	longer	on	average	than	similar	patients	who	do	not	choose	hospice	care,”772	although	the	authors	point	out	that	more	research	is	needed	before	generalizing	their	findings.773	Discussion	of	the	cost	of	the	mandate	In	2009,	22,406	persons	received	hospice	services	in	Massachusetts	through	Medicare	fee-for-service774	at	a	cost	of	almost	$231	million.775	Assessing	the	level	of	hospice	spending	in	Medicare	should	take	into	account	managed	care	plan	membership,	which	is	not	included	in	the	previously	cited	fee-for-service	figures.		In	2009,	23	percent	of	members	were	enrolled	in	Medicare	Advantage	plans.776		Assuming	that	Medicare	Advantage	members	utilize	hospice	services	at	the	same	rate	as	those	in	fee-for-service	plans,	the	estimated	spending	on	hospice	expense	for	Medicare	would	rise	to	approximately	$300	million	in	total.	According	to	the	Hospice	Association	of	America,	Medicare	represents	about	84.3	percent	of	spending	for	hospice	services.777		Based	on	this	proportion,	overall	spending	on	hospice	expenses	would	be	approximately	$356	million	in	2009.		National	Health	Expenditures	(NHE)	data	for	“other	health,	residential,	and	personal	care	expenditures”	reported	by	for	the	Centers	for	Medicare	and	Medicaid	Services	(CMS)	suggests	a	5-year	inflation	rate	of	21	percent	for	this	figure,778	yielding	an	estimate	of	$431	million	in	total	2014	hospice	spending.		The	portion	of	this	figure	paid	by	private	payers	is	approximately	7.8	percent,779	or	$33.6	million.		Applying	the	49.1	percent	Massachusetts	2014	fully-insured	factor	provides	an	estimate	of	$16.5	million	of	hospice	spending,	assuming	similar	per-case	costs	across	all	private	payers.		With	11	percent	administrative	loading,	the	total	spending	on	hospice	care	for	the	under-65	fully-insured	member	population	and	self-insured	GIC	enrollees	in	Massachusetts	in	2014	is	estimated	at	approximately	$18.5	million,	or	$0.65	PMPM,	representing	0.15	percent	of	the	overall	premium.		These	results	are	summarized	in	Table	35	below.	
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Moreover,	research	has	shifted	from	focusing	on	the	impact	of	high	BLLs	on	child	health	to	show	the	negative	impact	of	lower	BLLs	(below	10	mcg/dL)	on	childhood	development.	787	This	information	has	led	to	a	change	in	public	health	advocacy	from	recommending	screening	of	all	children	for	lead	exposure,	to	targeted	screening	for	certain	populations	and	a	primary	prevention	strategy	aimed	at	children	and	families	most	likely	to	live	in	homes	with	lead	hazards.		Many	of	the	recommendations	and	guidelines	issued	by	public	and	professional	medical	organizations	have	changed	over	time,	as	various	public	health	and	environmental	efforts	have	been	implemented	and	sometimes	phased	out,	with	other	approaches	evolving	and	replacing	them.788	For	example,	in	2012,	the	CDC	updated	its	recommendations	regarding	BLLs	in	children,	and	shifted	its	focus	to	primary	prevention	of	lead	exposure.		The	new	goals	are	to	eradicate	BLLs	greater	than	10	mcg/dL,	and	eliminate	average	risk	differences	that	exist	“based	on	race	and	social	class.”789		The	threshold	BLL	used	to	identify	children	who	need	medical	intervention	is	now	lower	and	will	be	periodically	adjusted,	rather	than	remaining	fixed	at	10	mcg/dL.790		This	public	health	initiative	is	part	of	the	National	Center	for	Environmental	Health's	Division	of	Emergency	and	Environmental	Health	Services,	and	is	in	line	with	the	Healthy	People	2020	program	of	the	federal	government,	which	revised	its	targets	for	reducing	BLLs	for	children	in	2014,	establishing	a	10	percent	improvement	goal	for	two	areas	of	measurement.791	According	to	the	American	Academy	of	Pediatrics	Bright	Futures	periodicity	table	of	Recommendations	for	Preventive	Pediatric	Health	Care,	a	lead	exposure	risk	assessment	is	recommended	at	preventive	health	visits	multiple	times	during	infancy	through	adolescence.792,793		Finger	stick	blood	sample	screenings	are	to	be	performed	at	the	12-	and	24-month	visits	if	a	patient	is	identified	through	screening,	lives	in	a	high-prevalence	area,	or	is	required	by	Medicaid	rules.794,795		These	rules	were	updated	for	children	eligible	for	Medicaid	Early	and	Periodic	Screening,	Diagnosis	and	treatment	(EPSDT)	services	in	June	2012	by	CMS.		This	policy	is	now	aligned	with	the	CDC	recommendations,	and	supports	a	targeted	screening	approach	“in	States	that	have	sufficient	data	to	support	this	action.”796	In	Massachusetts,	universal	screening	is	required	by	Department	of	Public	Health	regulations,	as	all	children	must	be	screened	for	lead	poisoning	at	least	twice:	once	between	nine	and	twelve	months	of	age,	and	again	between	two	and	three	years	of	age;	children	must	provide	evidence	of	screening	to	gain	entry	to	kindergarten.797		Children	living	in	areas	identified	as	high	risk	are	also	required	to	be	screened	at	age	four.798		Children	identified	by	health	care	providers	as	high-risk,	including	those	who	live	in	a	pre-1978	home	that	has	not	been	inspected	for	lead	paint,	or	who	have	siblings	identified	with	lead	poisoning,	should	be	screened	every	six	months	between	ages	six	months	and	three	years,	and	annually	at	ages	four	and	five.	799		And	children	living	in	a	pre-1978	home	undergoing	renovation	and	that	has	not	been	inspected	for	lead	paint	are	to	be	screened	within	four	weeks	of	the	start,	monthly	during,	and	once	after	completion	of	the	renovation.800	Only	those	screenings	conducted	at	age	four	for	children	living	in	areas	identified	as	high	risk,	or	those	for	children	identified	by	their	health	care	provider	as	high-risk,	are	subject	to	the	insurance	reimbursement	requirements	of	this	mandate.801	
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maternal	complications.840		Services	performed	in	the	post-partum/pre-discharge	stay	include	newborn	screenings	and	risk	assessment;	administration	of	immunizations;	maternal	and	family	counseling	and	assessments,	and	perinatal	education	on	issues	such	as	breast-feeding,	newborn	sleep	position,	tobacco	smoke	exposure,	car	seat	safety,	mental	health	including	post-partum	depression,	and	domestic	violence;	and	follow-up	care	planning	for	mother	and	baby.841	Post-partum	hospital	stays	for	mother	and	baby	have	changed	significantly	over	the	last	four	decades,	with	stays	for	vaginal	delivery	dropping	from	3.9	to	1.8	days	and	for	caesarian	deliveries	from	7.8	to	3.5	days	between	1970	and	1998.	842		Beginning	with	a	movement	to	“demedicalize”	childbirth,	followed	by	continued	pressure	to	reduce	costs,843	postpartum	lengths	of	stay	continued	to	decrease	until	the	mid-1990s.		In	1992,	the	AAP	and	ACOG	published	joint	guidelines	for	postpartum	hospital	stays,	including	a	48-hour	stay	for	an	uncomplicated	vaginal	birth,	and	a	96-hour	stay	for	an	uncomplicated	c-section,	excluding	the	day	of	delivery;	their	2007	publication	restated	these	guidelines.844		By	1997,	32	states	had	adopted	laws	intended	to	set	minimum	required	lengths	of	stay	following	delivery	for	both	mothers	and	newborns,	with	the	federal	government	enacting	the	federal	Newborns’	and	Mothers’	Health	Protection	Act	of	1996,	effective	in	1998.845		This	federal	law	provides	that	“[g]roup	health	plans	that	are	subject	to	the	Newborns’	Act	may	not	restrict	benefits	for	a	hospital	stay	in	connection	with	childbirth	to	less	than	48	hours	following	a	vaginal	delivery	or	96	hours	following	a	delivery	by	cesarean	section.	However,	the	attending	provider	may	decide,	after	consulting	with	the	mother,	to	discharge	the	mother	and/or	her	newborn	child	earlier.”846	In	some	states,	according	to	the	U.S.	Department	of	Labor,	“[b]ased	on	a	recent	preliminary	review	of	State	laws,	it	appears	that	State	law	applies	in	lieu	of	the	Federal	Newborns’	Act.”847,848	This	is	true	in	Massachusetts,	where	the	state	law	pertaining	to	minimum	inpatient	stays	following	birth	applies.		The	Massachusetts	statute	mandates	coverage	for	"expense	of	prenatal	care,	childbirth	and	postpartum	care	to	the	same	extent	as	provided	for	medical	conditions	not	related	to	pregnancy"	with	"minimum	48	hours	of	inpatient	care	following	a	vaginal	delivery	and	a	minimum	of	96	hours	of	inpatient	care	following	a	caesarean	section."849	The	most	current	APA	and	ACOG	recommendation	from	2013	states	that	“[t]he	length	of	stay	of	a	healthy	term	newborn	should	be	based	on	the	unique	characteristics	of	each	mother-infant	dyad,	including	the	health	of	the	mother,	the	health	and	stability	of	the	infant,	the	ability	and	confidence	of	the	mother	to	care	for	her	infant,	the	adequacy	of	support	systems	at	home,	and	access	to	appropriate	follow-up	care.”850,851		AAP	and	ACOG	further	outline	the	minimal	criteria	that	should	be	met	by	mother	and	newborn	when	the	physician	and	mother	want	a	shortened	hospital	stay,	stating	that	”[w]hen	no	complications	are	present,	the	postpartum	hospital	stay	usually	ranges	from	48	hours	for	vaginal	delivery	to	96	hours	for	cesarean	delivery,	excluding	the	day	of	delivery.”852,853		Other	studies	echo	this	conclusion,	stating	that	individualized	discharge	plans	“jointly	tailored	to	a	family's	needs	rather	than	to	a	set	timescale”	are	appropriate,	as	a	“lack	of	readiness”	for	postpartum	discharge	was	associated	with	poorer	health	outcomes	and	increased	health	care	use	by	patients	(mothers	and	newborns)	in	the	first	2	to	4	weeks	after	discharge.854	The	intended	and	observed	result	of	legislative	mandates	targeting	postpartum	length	of	stay	was	to	increase	average	length	of	stay	and	to	compress	variability	in	length	of	stay	among	population	
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The	National	Institutes	of	Health	estimates	that	18.5	percent	of	adults	have	a	mental,	behavioral,	or	emotional	disorder	(excluding	developmental	and	substance	use	disorders)	diagnosed	currently	or	within	the	past	year	of	duration	sufficient	“to	meet	diagnostic	criteria	specified	within	the	4th	edition	of	the	Diagnostic	and	Statistical	Manual	of	Mental	Disorders	(DSM-IV).”900		In	a	2013	survey	of	the	population	over	age	12,	8.2	percent	were	classified	with	a	substance	abuse	or	dependence	disorder	based	on	the	DSM-IV.901		For	adults	age	18	and	over	with	any	mental	illness,	17.5	percent	abused	or	were	dependent	on	alcohol	or	illicit	drugs;	this	number	rose	to	23	percent	for	those	with	a	serious	mental	illness.902	For	children	ages	13	to	18,	the	lifetime	prevalence	of	a	mental	disorder	is	43.8	percent,	and	over	20	percent	either	currently	or	at	some	point	in	their	lives	have	had	a	seriously	debilitating	mental	disorder.903		The	most	common	illness	for	children	was	attention	deficit-hyperactivity	disorder	with	a	prevalence	rate	of	8.6	percent,	followed	by	3.7	percent	with	mood	disorders,	and	2.7	percent	with	major	depression.904		In	2014,	14.8	percent	of	adults	in	the	United	States	received	treatment	(inpatient	or	outpatient	counseling	or	prescription	medication)	for	a	mental	health	problem,905	up	from	13.4	percent	in	2008.		Of	adults	with	any	mental	illness,	44.7	percent	received	treatment,	while	68.5	percent	for	those	with	serious	mental	illness	received	treatment.906	For	children	ages	8-15	with	a	diagnosed	mental	disorder,	50.6	percent	used	mental	health	services	in	the	last	year.907		Overall,	for	children	ages	12-17,	13.6	percent	received	specialty	mental	health	services	in	2014.908			Studies	linking	physical	and	mental	health	issues	continue	to	show	successful	treatment	of	mental	illness	is	critical	to	both	mental	and	physical	health.		Simply	put,	those	with	mental	illnesses	are	less	able	to	exercise	health-promoting	behaviors,	while	individuals	with	chronic	illnesses	are	more	likely	to	suffer	from	mental	health	issues	that	may	in	turn	impede	treatment	and	recovery.		Treatments	generally	fall	into	the	broad	categories	of	psychotherapy	and	medication,	and	may	incorporate	multimodal	therapy,	or	a	combination	of	the	two.		Psychotherapy	is	used	to	help	patients	understand	their	illnesses,	and	provides	tools	to	manage	symptoms	and	improve	function.		It	includes	such	commonly	used	methods	as	cognitive	behavioral	therapy,	dialectical	behavioral	therapy,	interpersonal	therapy,	and	family-focused	therapy.909		Other	therapies	include	psychodynamic,	light,	expressive	or	creative	arts,	animal-assisted,	and	play.910		Pharmacological	therapy	for	mental	illness	generally	refers	to	drugs	categorized	as	antipsychotics,	antidepressants,	mood	stabilizers,	antianxiety,	and	stimulants.911		New	treatments	include	brain	stimulation	therapy,	the	direct	activation	or	touching	of	the	brain	with	electricity,	magnets,	or	implants.912	Treatments	vary	by	individual,	illness,	and	other	factors	that	also	influence	a	patient’s	outcomes;	research	on	effectiveness	reflects	these	and	other	variables.	The	seminal	1999	U.S.	Surgeon	General’s	report	on	mental	illness	noted	that	“[t]he	efficacy	of	mental	health	treatments	is	well	documented,	and…a	range	of	treatments	exists	for	most	mental	disorders.”913		The	U.S.	Substance	Abuse	and	Mental	Health	Services	Administration	lists	almost	400	mental	health	and	substance	abuse	interventions	in	its	National	Registry	of	Evidence-Based	Programs	and	Practices.914,915		The	National	Institute	on	Drug	Abuse	(NIDA)	published	its	“Principles	of	Effective	Treatment”	for	substance	abuse	disorders,	outlining	general	points	that	research	has	shown	improve	outcomes	of	
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Paid	PMPM 16.06$													 N/A N/A
Paid	PMPM	With	Admin 18.05$													 N/A N/A
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Off-label	Use	of	Prescription	Drugs	to	Treat	Cancer	This	mandate	requires	the	Commissioner	of	Insurance	to	establish	a	panel	of	experts	to	review	off-label	uses	of	prescription	drugs	for	the	treatment	of	cancer	for	medical	appropriateness	and	to	direct	insurers	to	make	payments	consistent	with	those	recommendations.925	Effect	of	the	mandate	on	health	The	off-label	use	of	prescription	drugs	to	treat	cancer	mandate	requires	the	Commissioner	of	Insurance	to	establish	a	panel	of	experts	to	review	off-label	uses	of	prescription	drugs	for	the	treatment	of	cancer	for	medical	appropriateness	and	to	direct	insurers	to	make	payments	consistent	with	those	recommendations.	The	Federal	Food,	Drug	and	Cosmetics	Act	of	1938	created	the	Food	&	Drug	Administration	(FDA)	in	part	to	control	the	activities	of	pharmaceutical	and	medical	device	manufacturers	in	the	United	States.926		The	act	specifically	regulates	manufacturer’s	activities,	but	not	physician	prescribing	practices.927		When	the	FDA	approves	a	drug	for	market,	it	also	approves	its	labeling.		Labeling	is	specific	to	the	approved	indications	for	use,	dosage,	patient	population,	and	method	of	administration.928		Physicians,	however,	are	not	limited	to	prescribing	the	drug	according	to	its	label,	and	may	prescribe	drugs	for	“off-label”	uses,	or	those	not	specifically	approved	by	the	FDA.		However,	manufacturers	may	not	provide	information	about	off-label	uses	to	health	care	providers	or	patients,	except	reprints	of	peer-reviewed	research	articles	as	submitted	to	the	FDA,	and	only	for	those	products	for	which	the	manufacturer	is	seeking	supplemental	use	approval.929		Off-label	use	is	not	the	same	as	expanded	access	or	special	exemption,	which	are	FDA	processes	allowing	patients	not	eligible	for	clinical	trials	access	to	investigational	treatments	not	yet	FDA-approved.930	The	approval	process	for	drugs	can	take	between	eight	and	twelve	years;	for	every	5,000	to	10,000	compounds	that	begin	the	process,	only	one	receives	marketing	approval.931		Because	of	the	expense	and	time	needed	to	obtain	FDA-approved	use	of	a	drug,	off-label	prescribing	has	become	“an	integral	part	of	contemporary	medicine.”932		One	study	found	that	57	percent	of	new	drug	uses	come	from	field	discovery,	and	not	through	clinical	trials.933		Another	study,	published	in	2006,	found	that	21	percent	of	prescriptions	written	in	the	U.S.	were	for	off-label	use.934		The	practice	is	so	widespread	that	Consumer	Reports	magazine	publishes	a	guide	to	off-label	prescription	drugs,935	as	well	as	explanations	of	the	risks	and	benefits	of	off-label	uses.936		A	2008	survey	found	that	80	percent	of	oncologists	prescribe	off-label	treatments,	and	that	50	percent	of	chemotherapy	treatments	are	off-label	uses.937	Off-label	use	is	common	in	cancer	treatment	for	a	variety	of	reasons.		First,	certain	drugs	approved	for	treatment	of	specific	tumor	types	are	effective	against	a	broader	array	of	tumors.		Second,	cancer	is	often	treated	with	drug	combinations,	including	one	or	more	off-label.		These	combinations	change	frequently,	as	evidence	gathers	about	their	effectiveness.		Third,	cancer	treatment	continues	to	evolve	quickly.		Fourth,	oncologists	often	treat	terminal	patients	whose	approved	treatment	options	may	be	exhausted.		And	finally,	oncologists	may	be	more	open	than	are	other	specialists	to	experimenting	with	off-label	treatments	for	their	patients.938	
Comprehensive	Mandated	Benefit	Review	
compass Health Analytics 100 December 2016 
But	this	practice	is	not	without	significant	risks	and	controversy.		Critics	stress	the	risks	of	drugs	where	rigorous	scientific	evidence	does	not	exist	for	additional	applications;	such	dangers	may	range	from	a	drug’s	ineffectiveness	to	its	causing	outright	harm.		Clinical	study	protocols	and	the	FDA	itself	were	created	to	protect	patients	from	the	harm	of	unknown	outcomes	and	experimental	practices.		While	the	FDA	cannot	regulate	physician	prescribing,	malpractice	suits	against	practitioners	and	class	action	suits	against	manufacturers	have	increasingly	admitted	the	court	system	into	this	area	of	medicine,	bringing	with	them	the	threat	of	significant	financial	risk	and,	more	recently,	criminal	penalties.939,940		The	provider	community	itself	is	divided;	the	same	survey	of	oncologists	that	revealed	widespread	off-label	prescribing	found	that	“attitudes	and	practices…vary	substantially.”941	Despite	the	risks,	approved	treatment	options	remain	limited	for	certain	patients,	leaving	doctors	to	continue	to	prescribe	off-label	uses	for	drugs.		However,	no	widely	systematic	or	transparent	method	currently	exists	to	collect	information	on	off-label	use,	and	manufacturers	are	prohibited	from	distributing	any	such	information	they	collect.		One	study	found	the	use	of	off-label	medication	to	be	quite	common	in	outpatient	care,	with	most	(73	percent)	occurring	“without	scientific	support.”942		Further,	“[s]tudies	suggest	that	many	physicians	rely	on	experience,	anecdotal	reports,	and	opinion	leaders	to	guide	their	treatment	decisions,	often	failing	to	demand	solid	evidence	for	their	prescribing	choices.”943		Since	the	decision	to	prescribe	the	off-label	drug	is	a	professional	judgment,	and	the	mandate	is	by	nature	broad,	it	is	inevitable	that	some	uses	are	efficacious	while	others	are	not.	Professional	medical	societies	defend	the	rights	of	physicians	to	prescribe	pharmaceuticals	for	off-label	uses,	although	they	differ	in	the	strength	of	their	advocacy.		The	American	Medical	Association	(AMA)	“confirms	its	strong	support	for	the	autonomous	clinical	decision-making	authority	of	a	physician	and	that	a	physician	may	lawfully	use	an	FDA	approved	drug	product	or	medical	device	for	an	unlabeled	indication	when	such	use	is	based	upon	sound	scientific	evidence	and	sound	medical	opinion,”	and	calls	for	full	reimbursement	of	such	prescriptions	as	“reasonable	and	necessary	medical	care.”944		The	American	College	of	Physicians	(ACP)	states	that	“physicians	should	continue	to	be	able	to	prescribe	covered	drugs	for	accepted	off-label	uses,”	but	“opposes	any	efforts	to	weaken	FDA	authority	to	demand	rigorous	evaluations	of	drugs	and	medical	devices	for	both	safety	and	effectiveness	based	on	sound	scientific	and	medical	evidence	and	opposes	legislative	attempts	to	curtail	FDA	authority	to	establish	and	maintain	standards	of	safety	and	effectiveness	for	approval	of	drugs	and	medical	devices.”945		While	these	societies	leave	treatment	decisions	to	physicians,	each	encourages	its	members	to	study	available	information	to	determine	whether	off-label	prescribing	is	in	the	best	interest	of	the	patient.			For	anticancer	chemotherapeutic	regimens,	CMS	cites	three	compendia	recognized	in	the	Social	Security	Act	as	“authoritative	sources	for	use	in	the	determination	of	a	‘medically-accepted	indication’	of	drugs	and	biologicals	used	off-label	in	an	anticancer	chemotherapeutic	regimen.”946		These	include	the	American	Medical	Association	Drug	Evaluations	(AMA-DE),	United	States	Pharmacopoeia-Drug	Information	(USP-DI),	and	the	American	Hospital	Formulary	Service-Drug	Information	(AHFS-DI).947		Yet	a	study	of	these	found	that	while	oncologists	rely	on	compendia	for	off-label	indications	and	reimbursement	information,	even	these	“lack	transparency,	cite	little	
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current	evidence,	and	lack	systematic	methods	to	review	or	update	evidence.”948		The	ACP	states	that	“[w]hen	considering	an	innovative	therapy	that	has	no	precedent,	the	physician	should	consult	with	peers,	an	institutional	review	board,	or	other	expert	group	to	assess	the	risks,	potential	adverse	outcomes,	potential	consequences	of	foregoing	a	standard	therapy,	and	whether	the	innovation	is	in	the	patient's	best	interest.”949	Reimbursement	for	off-label	prescriptions	is	inconsistent	and	complex.		Many	states,	like	Massachusetts,	mandate	coverage	for	off-label	prescriptions	for	certain	types	of	drugs.		Likewise,	Medicare	Part	D	only	covers	payment	for	drugs	with	FDA	approval,	or	for	uses	supported	in	their	approved	drug	compendia,	including	DRUGDEX,	USP-DI,	and	AMA-DE.950		Further,	Part	B	will	pay	for	oral	anticancer	drugs	with	the	same	active	ingredients	and	indications	as	chemotherapy	drugs,	even	if	they	have	not	received	FDA	approval	for	that	use.951		However,	as	the	AMA-DE	and	USP-DI	are	no	longer	published,	the	issue	of	acceptable	compendia	has	become	even	more	complex.952			In	response	to	advocates’	calls	for	expanded	access	to	drugs	for	additional	uses,	the	FDA	has	done	much	in	recent	years	to	change	its	rulings	and	guidance	to	enable	distribution	of	therapies	which	have	proven	effective,	especially	in	cases	in	which	formal	approval	has	not	been	applied	for	or	granted.		The	2007	FDA	Amendments	Act	made	changes	that	impacted	off-label	prescribing.953		First	it	expands	information	collected	and	studied	about	drugs	following	approval.		The	agency	now	has	more	authority	to	monitor	safety	after	approval,	and	has	funding	to	set	up	a	stronger	post-marketing	surveillance	system	as	well	as	an	active	monitoring	system	to	discover	adverse	events	involving	a	drug.954		The	agency	is	empowered	to	use	large	clinical	databases	to	determine	a	drug’s	safety,	including	when	used	off-label,	and	may	now	order	manufacturers	to	conduct	post-approval	studies	to	identify	risks.	955		Second,	manufacturers	must	now	register	their	studies,	making	the	information	on	off-label	use	more	robust	and	available	to	physicians	and	the	public,	and	further	preventing	the	industry	from	hiding	negative	results	about	their	products.956		And	third,	the	FDA	has	more	power	to	act	when	a	product	appears	harmful,	including	the	ability	to	change	labeling	to	outline	harms	of	certain	off-label	drug	applications.957		An	example	is	labeling	changes	to	anti-depressants,	long	prescribed	off-label	to	teenagers	and	children	without	FDA	approval;	studies	demonstrated	that	these	drugs	may	increase	suicidal	thoughts	and	tendencies	in	younger	populations,	and	the	FDA	recently	added	this	warning	to	its	labels	for	prescribers	and	patients.		Furthermore,	the	FDA	can	limit	distribution	of	certain	drugs	only	to	physicians	with	specialized	training.	958		More	recently,	in	2009,	the	FDA	issued	non-binding	guidance	outlining	means	by	which	manufacturers	may	inform	physicians	of	unapproved	uses	for	approved	drugs	by	distributing	articles	from	independent	medical	and	scientific	resources.959	Despite	these	changes,	off-label	prescribing	is	still	widespread	in	the	practice	of	medicine.		However,	most	patients	are	not	aware	that	it	happens	at	all.		Physicians	are	not	required	to	inform	a	patient	that	a	prescribed	treatment	is	not	FDA	approved;	therefore,	patients	may	not	be	aware	of	the	treatment’s	uncertainty	and	potential	risks,	nor	of	the	potential	additional	cost	of	an	off-label	treatment	that	may	not	be	reimbursable.		In	fact,	one	poll	has	shown	that	half	of	patients	mistakenly	think	that	doctors	may	only	prescribe	drugs	for	FDA	approved	uses,	while	another	25	percent	are	not	sure	if	a	drug	must	be	approved	to	be	prescribed,	meaning	only	one-quarter	of	patients	are	aware	that	drugs	may	be	prescribed	for	unapproved	uses.		In	the	same	study,	almost	half	state	that	
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Resources	and	Services	Administration	(HRSA).989,990		This	latter	category	includes	a	schedule	of	services	outlined	in	the	Bright	Futures	Guidelines	for	Health	Supervision	of	Infants,	Children,	and	Adolescents,991,992	and	the	Recommendations	of	the	Secretary’s	Advisory	Committee	on	Heritable	Disorders	in	Newborns	and	Children,	including	its	Uniform	Screening	Panel.993		The	rationale	and	evidence	for	the	various	elements	of	the	American	Academy	of	Pediatrics	Bright	Futures	Guidelines	and	the	Uniform	Screening	Panel	is	summarized	in	Chapter	13	of	the	Bright	Futures	publication.994	Discussion	of	the	cost	of	the	mandate	The	preventive	care	mandate	requires	coverage	for	preventive	and	primary	care	services	for	children	up	to	age	six,	including	physical	exams,	sensory	screening,	neuropsychiatric	evaluation	and	developmental	screening,	hereditary	and	metabolic	screening	at	birth,	appropriate	immunizations,	blood	tests,	and	urinalysis.	Under	Section	2713	of	the	ACA,	commercial	insurance	plans	must	provide	coverage	for	a	range	of	preventive	services	without	imposing	cost-sharing	requirements	(such	as	copayments,	deductibles,	or	co-insurance).		For	infants,	children,	and	adolescents,	these	services	include	evidenced-informed	preventive	care	and	screenings	recommended	by	the	Health	Resources	and	Services	Administration	and	outlined	in	the	Bright	Futures	Guidelines.		These	preventive	health	services	apply	to	all	commercial	plans	(individual,	small	group,	large	group,	and	self-insured	plans),	unlike	other	essential	health	benefits	(EHBs)	that	apply	only	to	individual	and	small	group	plans.995	To	calculate	the	effect	of	the	preventive	care	mandate	on	commercial	insurance	costs	in	Massachusetts,	Compass	reviewed	a	2005	study	that	examined	components	of	preventive	care	for	both	“not-at-risk”	and	“at-risk”	children.	Multiplying	each	average	preventive	service	cost	by	an	estimated	42,000	children	and	summing	the	product	results	in	an	estimate	of	$106	million,	or	$2.95	PMPM.		These	costs	do	not	include	neuropsychiatric	evaluations,	as	they	were	not	included	in	the	cited	cost	study.		However,	the	costs	do	include	newborn	hearing	screening,	costs	for	which	were	estimated	in	the	“Newborn	Hearing	Screening”	section	above.		Lacking	more	specific	data,	Compass	assumes	that	the	costs	for	hearing	screening	and	neuropsychiatric	evaluations	are	approximately	equal,	and	that	any	difference	is	within	the	range	of	estimation	error	for	the	preventive	care	mandate	as	a	whole.		Based	on	this	assumption,	Compass	trended	the	2005	estimate	forward	to	2014	using	NHE	physician	and	clinical	expense	private	insurer	expense	data996	to	obtain	a	2014	estimated	PMPM	paid	claim	amount	for	preventive	care	for	children	under	age	6	of	$4.31	PMPM	($122.1	million),	or	a	$4.84	total	cost	PMPM	amount	($137.2	million)	and	a	1.11	percent	of	total	Commonwealth	premium	calculation	with	11	percent	administrative	loading.	These	results	are	summarized	in	Table	40	below.	
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Paid	PMPM 4.31$																 N/A N/A
Paid	PMPM	With	Admin 4.84$																 N/A N/A
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To	measure	the	mandates’	full	impact,	insurer	administrative	costs	need	to	be	added.		In	the	next	two	columns	of	Table	41	the	lower	bound	estimate	of	$46.9	million	becomes	$52.7	million	with	administration,	and	the	upper	bound	estimate	becomes	$796.8	million	after	removing	zero	marginal	cost	mandates	and	adding	administrative	expense.			The	range	of	the	marginal	direct	cost	impact	of	all	39	mandate	laws	studied,	including	administrative	costs,	is	therefore	between	$52.7	million	and	$796.8	million.		The	true	value	is	not	likely	to	be	near	either	end	of	this	range.		The	upper	end	of	the	range	includes	all	RDCs	except	those	for	mandates	judged	by	the	carriers	likely	to	have	zero	marginal	costs,	and	includes	an	additional	provision	for	carrier	administrative	costs.		This	upper	bound	estimate	assumes	that	100	percent	of	the	RDC	for	mandates	with	potential	marginal	direct	cost	is	marginal,	and	that	carriers	would	pay	zero	dollars	in	claims	for	the	services	described	by	the	mandates	in	the	absence	of	the	mandate	laws.		The	lower	end	of	the	range	subtracts	from	the	RDCs	the	dollars	implied	by	the	per	person	spending	rate	in	the	self-insured	market,	which	is	not	subject	to	the	mandate	laws.		This	estimate	assumes	that	100	percent	of	the	spending	for	the	mandates	with	potential	marginal	direct	cost	in	the	self-insured	market	would	occur	in	the	absence	of	the	mandate	laws,	and	that	none	of	the	spending	is	influenced	by	the	mandated	spending	levels	in	the	fully-insured	market.	The	range	of	estimates	is	associated	with	between	0.43	percent	of	premium	for	the	low-end	estimate	and	6.45	percent	for	the	high-end	estimate.		The	estimated	range	does	not	consider	indirect	costs,	which,	as	noted	above,	previous	research	finds	will	increase	costs	for	some	mandates	and	offset	costs	for	others.			The	two	most	expensive	mandates	in	the	potential	marginal	direct	cost	group	are	home	health	care	services	($0	to	$289	million	gross	of	mandate	overlaps)	and	diabetes-related	services	and	supplies	($0	to	$197.5	million	gross	of	mandate	overlaps).		Both	are	provided	in	the	self-insured	market	at	the	same	or	higher	levels	than	they	are	provided	in	the	fully-insured	market,	suggesting	that	these	benefits	are	cost-effective,	popular	with	employees,	or	both.		Combined,	and	with	overlaps	removed,	these	two	mandates	have	a	low-end	estimate	of	0	percent	of	premium	and	a	high-end	estimate	of	3.8	percent	of	premium.	
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Unduplicated	Total	All	Mandates 1,912.96$																			 46.94$																			 52.74$														 796.81$														 0.43% 6.45%
Mandates	with	Potential	Marginal	Direct	Cost
Service	Mandates
Autism	Spectrum	Disorders	Services 39.54$																								 15.25$																			 17.13$														 44.42$																 0.14% 0.36%
Chiropractic	Services 2.68$																											 0.94$																					 1.06$																 3.01$																		 0.01% 0.02%
Child	Hearing	Aids 6.89$																											 -$																							 -$																		 7.74$																		 0.00% 0.06%
Cleft	Palate	and	Lip 3.30$																											 0.10$																					 0.12$																 3.70$																		 0.00% 0.03%
Diabetes-related	Services	and	Supplies 175.79$																						 -$																							 -$																		 197.52$														 0.00% 1.60%
Early	Intervention	Services 25.72$																								 2.78$																					 3.12$																 28.90$																 0.03% 0.23%
Home	Health	Care 257.25$																						 -$																							 -$																		 289.04$														 0.00% 2.34%
Hormone	Replacement	Therapy	(HRT) 11.56$																								 0.74$																					 0.83$																 12.99$																 0.01% 0.11%
Human	Leukocyte	Antigen	Testing 0.02$																											 -$																							 -$																		 0.02$																		 0.00% 0.00%
Hypodermic	Syringes	or	Needles 1.08$																											 -$																							 -$																		 1.22$																		 0.00% 0.01%
Infertil ity	Treatment 104.73$																						 12.67$																			 14.24$														 117.67$														 0.12% 0.95%
Low	Protein	Food	Products	for	Inherited	Amino	
			Acid	and	Organic	Acid	Diseases	(PKU)
Nonprescription	Enteral	Formulas 0.92$																											 -$																							 -$																		 1.04$																		 0.00% 0.01%
Oral	Cancer	Drugs 1.38$																											 0.49$																					 0.55$																 1.55$																		 0.00% 0.01%
Prosthetic	Limbs	and	Associated	Services 3.87$																											 -$																							 -$																		 4.35$																		 0.00% 0.04%
Scalp	Hair	Prostheses	for	Cancer	Patients 0.41$																											 -$																							 -$																		 0.46$																		 0.00% 0.00%
Speech,	Hearing	and	Language	Disorders 7.12$																											 -$																							 -$																		 8.00$																		 0.00% 0.06%
Provider	Mandates
Certified	Nurse	Midwives 1.62$																											 -$																							 -$																		 1.83$																		 0.00% 0.01%
Certified	Registered	Nurse	Anesthetists 22.09$																								 -$																							 -$																		 24.83$																 0.00% 0.20%
Chiropractors 7.97$																											 0.81$																					 0.91$																 8.96$																		 0.01% 0.07%
Dentists 1.39$																											 -$																							 -$																		 1.56$																		 0.00% 0.01%
Nurse	Practitioners 44.63$																								 9.31$																					 10.46$														 50.15$																 0.08% 0.41%
Optometrists 6.23$																											 -$																							 -$																		 7.00$																		 0.00% 0.06%
Physician	Assistants 41.01$																								 2.01$																					 2.26$																 46.07$																 0.02% 0.37%
Podiatrists 16.38$																								 0.81$																					 0.91$																 18.41$																 0.01% 0.15%
Mandates	Judged	to	Have	Zero	Marginal	Cost
Bone	Marrow	Transplants	for	Treatment	of	Breast	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Cardiac	Rehabilitation 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Clinical	Trials	(to	treat	cancer) 2.28$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Contraceptive	Services 94.20$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Cytologic	Screening 17.54$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Hearing	Screening	for	Newborns 3.32$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Hospice	Care 16.49$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Lead	Poisoning	Screening 1.20$																											 -$																							 -$																		 -$																				 0.00% 0.00%
Mammography 17.69$																								 -$																							 -$																		 -$																				 0.00% 0.00%
Maternity	Health	Care	(including	minimum	maternity	stay) 471.27$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Mental	Health	Care 455.40$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Preventive	Care	for	Children	Up	to	Age	Six	 122.14$																						 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	Cancer -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
Off-Label	Uses	of	Prescription	Drugs	to	Treat	HIV/AIDS -$																													 -$																							 -$																		 -$																				 0.00% 0.00%
0.01%1.53$																											 0.08$																					 1.71$																		0.09$																 0.00%
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pressure	on	the	benefits	offered	by	self-insured	firms.		However,	the	need	for	self-insured	firms	to	not	disadvantage	themselves	in	the	labor	market	in	the	presence	of	the	fully-insured	firms	with	mandated	benefit	coverage	seems	certain	to	influence	benefit	levels.		The	magnitude	of	any	such	effect	would	increase	the	impact	estimate	above	$52.7	million,	and	would	vary	by	mandate.		Certain	highly-visible	and	expensive	benefits	such	as	infertility	treatment	($117.7	million)	would	seem	most	subject	to	upward	pressure	of	the	labor	market.		On	the	other	hand,	for	many	of	the	mandates	in	Table	41,	the	per-person	allowed	costs	are	actually	higher	in	the	self-insured	market	than	in	the	fully-insured	market	(those	with	a	zero	lower-bound),	suggesting	no	upward	pressure	induced	by	the	fully-insured	market.			Applying	both	these	lines	of	reasoning	to	narrow	the	range	displayed	in	Table	42,	it	seems	likely	that	the	direct	cost	impact	of	the	mandates	is	somewhere	between	one	percent	and	four	percent	of	total	premium.			In	addition	to	the	direct	cost	impacts,	there	are	indirect	cost	effects	on	other	service	categories	not	directly	affected	by	the	mandate	that	Compass	is	not	able	to	address	in	this	study.		Some	of	these	indirect	costs	may	increase	overall	costs,	such	as	additional	births	resulting	from	fertility	treatment,	while	others	would	reduce	costs,	such	as	hospitalizations	avoided	as	result	of	diabetes	coverage.		To	the	extent	that	mandates	induce	utilization	increases	within	the	services	addressed	by	a	mandate,	such	costs	are	covered	in	both	the	RDC	upper	bound	estimates	and	the	lower	bound	estimates.		About	75	percent	of	the	total	estimated	direct	cost	stems	from	three	of	the	mandates:		home	health,	diabetes	services	and	supplies,	and	infertility;	nearly	an	additional	20	percent	is	comprised	by	the	provider	mandates.		Consideration	of	these	eleven	mandates	and	their	likely	indirect	cost	effects	would	provide	most	of	the	required	information	on	how	the	direct	costs	might	be	increased	or	reduced	by	indirect	cost	effects.		It	is	possible	that	after	consideration	of	indirect	cost	effects,	the	net	impact	of	these	eleven	mandates	is	cost	reducing,	though	we	cannot	estimate	that	impact	in	this	study.		Finally,	there	are	individual	and	socially	beneficial	impacts	aside	from	health	care	spending	that	these	mandates	may,	and	in	many	cases	certainly	do,	provide.		Benefit	mandates	are	often	enacted	when	such	beneficial	effects	are	widely	perceived	but	something	short	of	government	provision	of	the	benefit	is	the	balance	point	of	the	political	process.997			 	
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mandates	apply	to	residents	of	Massachusetts	and	to	those	with	a	principal	place	of	employment	in	Massachusetts,	and	so	effectively	apply	to	all	members	covered	by	fully-insured	policies	issued	in	Massachusetts.		There	are	a	few	exceptions	to	this	general	case	apparent	in	the	statutory	language.		First,	the	infertility	mandate	applies	only	to	Massachusetts	residents.		The	infertility	sample	cost	estimates	therefore	include	only	those	claims	and	members	indicating	a	member	state	of	residence	of	Massachusetts,	and	the	population	paid	expenses	PMPM	are	calculated	over	the	member-resident	insured	population	only.		Second,	four	provider	mandates	(certified	nurse	midwives,	chiropractors,	dentists,	and	optometrists)	do	not	have	language	in	Chapter	176G	(the	HMO	license).		As	a	result,	in	our	calculations	we	have	not	applied	the	cost	estimates	to	this	population	for	these	four	mandates.		Third,	the	chiropractic	services	mandate	applies	only	to	medical	service	corporations	(Chapter	176B),	and	as	a	result	the	cost	estimates	are	applied	only	to	the	BCBSMA	membership.	
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Mandate A B C D E F G H I J K L M N O P





F Diabetes	Services	Mandate 12.1$	 0.2$			 0.1$			 0.5$			
G Early	Intervention	Services	Mandate 14.9$	 0.3$			
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incidence	of	an	illness	and	cost	per	episode	of	that	illness	were	multiplied	together	to	produce	the	estimate.		In	all	cases,	the	costs	estimated	were	total	required	direct	costs.		As	discussed	above,	marginal	direct	cost	for	each	mandate	in	the	secondary	cost	group	is	assumed	to	be	zero.			Most	of	the	estimates	relying	on	secondary	data	drew	on	sources	that	were	not	specific	to	the	fully-insured	population	in	Massachusetts.		As	a	result,	data	from	broader	populations	(e.g.,	Massachusetts	statewide)	had	to	be	adjusted	to	the	sub-population	using	population	estimates	drawn	from	a	number	of	sources,	including	Census	Bureau	data	and	a	model	of	the	Massachusetts	insured	population	developed	by	Compass	for	its	work	for	CHIA.		These	estimates	and	their	sources	are	summarized	in	Appendix	C.		 	
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Appendix	C:	Estimation	of	Population	Subsets	Membership	potentially	affected	by	a	proposed	mandate	may	include	Massachusetts	residents	with	fully-insured	employer-sponsored	health	insurance	issued	by	a	Massachusetts	licensed	company	(including	through	the	GIC),	non-residents	with	fully-insured	employer-sponsored	insurance	issued	in	Massachusetts,	Massachusetts	residents	with	individual	(direct)	health	insurance	coverage,	and	lives	covered	by	GIC	self-insured	coverage	(which	complies	with	the	mandates	voluntarily).		Membership	projections	for	2017	to	2021	are	derived	from	the	following	sources.	The	2014	Massachusetts	All	Payer	Claim	Database	(MA	APCD)	formed	the	base	for	the	projections.		The	APCD	provided	fully-insured	and	self-insured	membership	by	insurance	carrier.		The	APCD	was	also	used	to	estimate	the	number	of	non-residents	covered	by	a	Massachusetts	policy.		These	are	typically	cases	in	which	a	non-resident	works	for	a	Massachusetts	employer	offering	employer-sponsored	coverage.	The	Massachusetts	Center	for	Health	Information	and	Analysis	(CHIA)	uses	supplemental	information	beyond	the	data	in	the	MA	APCD	to	develop	their	enrollment	trends	reports	and	provided	us	with	information	on	where	they	sourced	the	data	in	their	report	(MA	APCD	and	supplemental	carrier	information).		We	adjusted	our	membership	estimates	for	the	data	not	in	the	MA	APCD	where	appropriate.		The	2014	combined	membership	projection	by	carrier	was	compared	to	Massachusetts	Department	of	Insurance	(DOI)	reports	estimating	fully-insured	covered	members	by	insurance	carrier.		The	membership	projections	were	increased	to	include	insurance	carriers	that	were	reported	by	the	DOI	but	not	in	the	MA	APCD	or	CHIA	supplementary	report.		These	were	typically	insurance	carriers	with	small	membership	in	the	state.		The	distribution	of	members	by	age	and	gender	was	estimated	using	MA	APCD	population	distribution	ratios	and	was	checked	for	reasonableness	and	validated	against	the	U.S.	Census1017.		Membership	was	projected	forward	from	the	2014	base	year	through	2021	using	Census	Bureau	population	growth	rate	estimates	by	age	and	gender1018.		Projections	for	the	GIC	self-insured	lives	were	developed	using	GIC	base	data	for	2013,1019	2014,1020	and	2015,1021	and	the	same	projected	growth	rates	from	the	Census	Bureau	that	were	used	for	the	Massachusetts	population.		Breakdowns	of	the	GIC	self-insured	lives	by	gender	and	age	were	based	on	the	Census	Bureau	distributions.		 	
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Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $31,316,705 $39,537,136 1.39$						





Chiropractic	Manipulative	Treatment $2,304,438 $2,677,008 1.35$				
All	Services $2,304,438 $2,677,008 1.35$				
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Inpatient	Services $690,412 $871,641 0.031$	
Surgery,	Digestive	System $525,878 $663,917 0.023$	
Anesthesia $275,765 $348,151 0.012$	
Surgery,	Respiratory	System $160,822 $203,037 0.007$	
Office/Other	Outpatient	Services $156,818 $197,982 0.007$	
Hospital	Observation	Services $107,889 $136,210 0.005$	
Surgery,	Musculoskeletal	System $102,106 $128,908 0.005$	
Surgery,	Integumentary	System $98,350 $124,166 0.004$	
Special	Otorhinolaryngologic	Services $81,405 $102,773 0.004$	
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	Care	Services $71,858 $90,720 0.003$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $41,161 $51,966 0.002$	
Pathology	&	Laboratory $35,582 $44,922 0.002$	
Dental	Procedures $32,477 $41,003 0.001$	
Temporary	National	Codes	Est.	by	Private	Payers $32,189 $40,638 0.001$	
Enteral	and	Parenteral	Therapy $30,534 $38,549 0.001$	
Surgery,	Auditory	System $23,907 $30,182 0.001$	
Hospital	Inpatient	Services $16,754 $21,152 0.001$	
Radiology $14,483 $18,285 0.001$	
Durable	Medical	Equipment $13,180 $16,640 0.001$	
Drugs	Other	Than	Chemotherapy $12,101 $15,277 0.001$	
Transport	Services	Including	Ambulance $11,322 $14,294 0.001$	
Preventive	Medicine	Services $10,523 $13,286 0.000$	
Consultations $10,301 $13,005 0.000$	
CMS	Hospital	Outpatient		Payment	System $9,322 $11,769 0.000$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $8,679 $10,957 0.000$	
Temporary	National	Codes	Est.	by	Medicaid $8,438 $10,653 0.000$	
Unclassified	Services $4,205 $5,309 0.000$	
Immunization	Administration	for	Vaccines/Toxoids $4,153 $5,243 0.000$	
Surgery,	Male	Genital	System $3,217 $4,062 0.000$	
Emergency	Department	Services $2,567 $3,240 0.000$	
Ophthalmology $2,226 $2,811 0.000$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	Mental	Status,	Speech	Testing)$1,904 $2,403 0.000$	
Medical	&	Surgical	Supplies $1,745 $2,203 0.000$	
Cardiovascular $1,657 $2,092 0.000$	
Psychiatry $1,184 $1,494 0.000$	
Health	&	Behavior	Assessment/Intervention $1,177 $1,486 0.000$	
Temporary	Procedures	&	Professional	Services $979 $1,236 0.000$	
Vaccines,	Toxoids $811 $1,024 0.000$	
Critical	Care	Services $794 $1,003 0.000$	
Special	Services,	Procedures,	and	Reports $535 $675 0.000$	
Newborn	Care	Services $362 $457 0.000$	
Pulmonary $102 $129 0.000$	
Qualifying	Circumstances	for	Anesthesia $66 $84 0.000$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$41 $51 0.000$	
Temporary	Codes	for	Durable	Medical	Equipment	Regional	Carriers $28 $35 0.000$	
Other	Services	&	Procedures $23 $28 0.000$	
Surgery,	Cardiovascular	System $19 $23 0.000$	
All	Services $2,610,049 $3,295,170 0.12$				
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Pharmacy	Claims $87,417,466 $143,654,795 5.067$	
Administrative,	Miscellaneous	&	Investigational $4,891,877 $8,038,916 0.284$	
Pathology	&	Laboratory $4,101,261 $6,739,681 0.238$	
Medical	&	Surgical	Supplies $3,853,956 $6,333,280 0.223$	
Durable	Medical	Equipment $3,391,982 $5,574,109 0.197$	
Temporary	Procedures	&	Professional	Services $1,496,366 $2,459,007 0.087$	
Medical	Nutrition	Therapy $1,117,904 $1,837,073 0.065$	
Ophthalmology $387,196 $636,286 0.022$	
Surgery,	Integumentary	System $187,048 $307,380 0.011$	
Endocrinology $54,092 $88,890 0.003$	
Preventive	Medicine	Services $44,919 $73,816 0.003$	
Drugs	Other	Than	Chemotherapy $13,032 $21,416 0.001$	
Temporary	National	Codes	Est.	by	Private	Payers $10,795 $17,740 0.001$	
Orthotics $5,758 $9,462 0.000$	





Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $14,216,047 $17,947,666 0.633$	
Temporary	National	Codes	Est.	by	Medicaid $4,683,775 $5,913,236 0.209$	
Health	&	Behavior	Assessment/Intervention $1,469,498 $1,855,232 0.065$	
Consultations $225 $284 0.000$	
Office/Other	Outpatient	Services $171 $216 0.000$	
Preventive	Medicine	Services $57 $72 0.000$	





Special	Otorhinolaryngologic	Services $4,701,980 $5,936,219 0.209$	
Hearing	Services $753,459 $951,237 0.034$	
Surgery,	Auditory	System $4,344 $5,485 0.000$	
All	Services $5,459,783 $6,892,940 0.24$				
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Drugs	Other	Than	Chemotherapy $54,578,177 $68,904,593 2.430$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $40,163,888 $50,706,647 1.788$	
Durable	Medical	Equipment $26,135,778 $32,996,250 1.164$	
Medical	&	Surgical	Supplies $18,237,749 $23,025,039 0.812$	
Temporary	National	Codes	Est.	by	Private	Payers $13,660,316 $17,246,060 0.608$	
Unclassified	Services $9,529,481 $12,030,907 0.424$	
Orthotics $7,042,962 $8,891,693 0.314$	
Administrative,	Miscellaneous	&	Investigational $6,760,780 $8,535,441 0.301$	
Temporary	Procedures	&	Professional	Services $5,592,887 $7,060,983 0.249$	
Enteral	and	Parenteral	Therapy $5,068,539 $6,398,998 0.226$	
Inpatient	Services $4,804,697 $6,065,899 0.214$	
Prosthetics $3,171,974 $4,004,596 0.141$	
Temporary	Codes	for	Durable	Medical	Equipment	Regional	Carriers $2,506,788 $3,164,803 0.112$	
Home	Health	Procedures/Services $2,058,987 $2,599,457 0.092$	
Temporary	National	Codes	Est.	by	Medicaid $1,332,662 $1,682,477 0.059$	
Psychiatry $537,907 $679,104 0.024$	
Pulmonary $524,226 $661,831 0.023$	
Physical	Medicine	&	Rehabilitation $291,259 $367,713 0.013$	
Special	Otorhinolaryngologic	Services $260,045 $328,305 0.012$	
Home	Services $252,856 $319,229 0.011$	
Vision	Services $219,560 $277,194 0.010$	
Pathology	&	Laboratory $173,408 $218,926 0.008$	
Temporary	Codes	Assigned	by	CMS $155,657 $196,516 0.007$	
Chemotherapy	Drugs $103,538 $130,716 0.005$	
Surgery,	Musculoskeletal	System $94,206 $118,935 0.004$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $70,925 $89,542 0.003$	
Neurology	&	Neuromuscular	Procedures $67,448 $85,153 0.003$	
Hearing	Services $62,335 $78,697 0.003$	
Health	&	Behavior	Assessment/Intervention $54,879 $69,285 0.002$	
Dialysis $45,710 $57,708 0.002$	
Surgery,	Maternity	Care	&	Delivery $28,763 $36,314 0.001$	
Vaccines,	Toxoids $20,090 $25,363 0.001$	
Transport	Services	Including	Ambulance $18,439 $23,279 0.001$	
Surgery,	Nervous	System $17,000 $21,462 0.001$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $13,844 $17,478 0.001$	
Cardiovascular $13,547 $17,103 0.001$	
Preventive	Medicine	Services $10,153 $12,819 0.000$	
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	Services $10,110 $12,764 0.000$	
Hospital	Inpatient	Services $8,770 $11,073 0.000$	
Office/Other	Outpatient	Services $8,118 $10,249 0.000$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	
Mental	Status,	Speech	Testing) $6,869 $8,673 0.000$	
Domicil iary,	Rest	Home	(assisted	l iving	facil ity)	or	Home	Plan	
Oversight	Services $6,684 $8,439 0.000$	
Laboratory	Services $6,122 $7,729 0.000$	
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Anesthesia $5,608 $7,080 0.000$	
Education	&	Training	for	Patient	Self-Management $4,270 $5,390 0.000$	
Special	Dermatological	Procedures $2,943 $3,715 0.000$	
Surgery,	Integumentary	System $2,602 $3,285 0.000$	
Radiology $1,869 $2,360 0.000$	
Immunization	Administration	for	Vaccines/Toxoids $1,640 $2,070 0.000$	
Ophthalmology $1,636 $2,065 0.000$	
Special	Services,	Procedures,	and	Reports $1,525 $1,925 0.000$	
Diagnostic	Radiology	Services $1,331 $1,680 0.000$	
Surgery,	Eye	&	Ocular	Adnexa $1,250 $1,578 0.000$	
Care	Plan	Oversight	Services $1,228 $1,550 0.000$	
Surgery,	Male	Genital	System $1,126 $1,422 0.000$	
Other	Services	&	Procedures $966 $1,220 0.000$	
Surgery,	Cardiovascular	System $774 $977 0.000$	
Surgery,	Digestive	System $706 $891 0.000$	
Newborn	Care	Services $655 $827 0.000$	
Consultations $591 $746 0.000$	
Chiropractic	Manipulative	Treatment $534 $674 0.000$	
Case	Management	Services $380 $480 0.000$	
Nursing	Facil ity	Services $261 $330 0.000$	
Surgery,	Auditory	System $138 $175 0.000$	
Other	Evaluation	and	Management	Services $115 $145 0.000$	
Noninvasive	Vascular	Diagnostic	Studies $107 $135 0.000$	
Surgery,	Female	Genital	System $81 $102 0.000$	
Medical	Nutrition	Therapy $79 $100 0.000$	
Surgery,	Respiratory	System $77 $98 0.000$	
Moderate	(conscious)	Sedation $74 $93 0.000$	
Surgery,	Urinary	System $73 $92 0.000$	
Allergy	&	Clinical	Immunology $2 $3 0.000$	
Prolonged	Services $0 $0 -$						
All	Services $203,760,773 $257,246,649 9.07$				
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Pharmacy	Claims $5,873,488 $9,652,016 0.340$	
Office/Other	Outpatient	Services $711,427 $1,169,101 0.041$	
Preventive	Medicine	Services $398,042 $654,110 0.023$	
Pathology	&	Laboratory $23,108 $37,974 0.001$	
Consultations $15,544 $25,544 0.001$	
Surgery,	Integumentary	System $11,183 $18,377 0.001$	
Drugs	Other	Than	Chemotherapy $4,154 $6,827 0.000$	





Pathology	&	Laboratory $14,526 $18,339 0.001$	





Pharmacy $496,900 $816,566 0.029$	
Medical	&	Surgical	Supplies $162,308 $266,724 0.009$	
All	Services $659,209 $1,083,290 0.04$				
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Pharmacy	Claims $28,614,597 $54,302,681 2.051$	
Temporary	National	Codes	Est.	by	Private	Payers $17,916,345 $34,000,324 1.284$	
Surgery,	Female	Genital	System $3,677,979 $6,979,798 0.264$	
Pathology	&	Laboratory $2,224,355 $4,221,218 0.159$	
Office/Other	Outpatient	Services $1,641,581 $3,115,273 0.118$	
Radiology $431,432 $818,741 0.031$	
Preventive	Medicine	Services $239,984 $455,424 0.017$	
Surgery,	Auditory	System $224,577 $426,186 0.016$	
Consultations $150,025 $284,707 0.011$	
Special	Otorhinolaryngologic	Services $35,647 $67,649 0.003$	
Surgery,	Digestive	System $20,129 $38,200 0.001$	
Surgery,	Maternity	Care	&	Delivery $8,990 $17,060 0.001$	





Enteral	and	Parenteral	Therapy $1,144,495 $1,444,918 0.051$	
Temporary	National	Codes	Est.	by	Private	Payers $64,152 $80,992 0.003$	





Enteral	and	Parenteral	Therapy $732,663 $924,982 0.033$	
All	Services $732,663 $924,982 0.03$				
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Pharmacy $44,508,253 $73,141,263 2.580$	
Drugs	Other	Than	Chemotherapy $12,323 $20,251 0.001$	





Prosthetics $3,063,784 $3,868,008 0.136$	





A9282 Wig,	any	type,	each $325,539 $410,990 0.014$	
All	Services $325,539 $410,990 0.01$				
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Special	Otorhinolaryngologic	Services $3,210,954 $4,053,808 0.143$	
Hearing	Services $735,387 $928,422 0.033$	
Surgery,	Auditory	System $711,401 $898,140 0.032$	
Prosthetics $600,349 $757,937 0.027$	
Inpatient	Services $280,689 $354,368 0.012$	
Central	Nervous	System	Assessments/Tests	(Neuro-
Cognitive,	Mental	Status,	Speech	Testing) $37,459 $47,292 0.002$	
Temporary	Procedures	&	Professional	Services $24,772 $31,275 0.001$	
Surgery,	Digestive	System $7,928 $10,009 0.000$	
Hospital	Observation	Services $7,618 $9,617 0.000$	
Surgery,	Integumentary	System $3,258 $4,113 0.000$	
Radiology $3,073 $3,880 0.000$	
Surgery,	Musculoskeletal	System $2,927 $3,695 0.000$	
Pathology	&	Laboratory $2,879 $3,635 0.000$	
Drugs	Other	Than	Chemotherapy $2,612 $3,297 0.000$	
Cardiovascular $1,833 $2,314 0.000$	
Anesthesia $1,669 $2,108 0.000$	
Medical	&	Surgical	Supplies $618 $780 0.000$	
Neurology	&	Neuromuscular	Procedures $517 $653 0.000$	
Temporary	National	Codes	Est.	by	Private	Payers $305 $385 0.000$	
CMS	Hospital	Outpatient		Payment	System $177 $223 0.000$	
Pulmonary $97 $122 0.000$	
Temporary	Codes	Assigned	by	CMS $71 $89 0.000$	
Surgery,	Cardiovascular	System $9 $12 0.000$	
Ophthalmology $2 $2 0.000$	
Surgery,	Respiratory	System $0 $0 0.000$	
Administrative,	Miscellaneous	&	Investigational $0 $0 -$						
All	Services $5,636,603 $7,116,174 0.25$				
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Surgery,	Maternity	Care	&	Delivery $187,264 $962,380 0.110$			
Preventive	Medicine	Services $29,820 $153,249 0.017$			
Pathology	&	Laboratory $26,547 $136,430 0.016$			
Unclassified	Services $23,392 $120,216 0.014$			
Office/Other	Outpatient	Services $20,466 $105,178 0.012$			
Drugs	Other	Than	Chemotherapy $15,298 $78,618 0.009$			
Vaccines,	Toxoids $3,830 $19,685 0.002$			
Immunization	Administration	for	Vaccines/Toxoids $3,332 $17,123 0.002$			
Surgery,	Female	Genital	System $2,533 $13,018 0.001$			
Temporary	Codes	Assigned	by	CMS $822 $4,222 0.000$			
Surgery,	Integumentary	System $591 $3,037 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$571 $2,932 0.000$			
Hospital	Observation	Services $556 $2,858 0.000$			
Immune	Globulins,	Serum,	or	Recombinant	Prods $467 $2,399 0.000$			
Home	Services $156 $802 0.000$			
Emergency	Department	Services $149 $764 0.000$			
Surgery,	Male	Genital	System $99 $511 0.000$			
Temporary	National	Codes	Est.	by	Private	Payers $90 $463 0.000$			
Surgery,	Cardiovascular	System $79 $406 0.000$			
Hospital	Inpatient	Services $0 $0 -$							
All	Services $316,062 $1,624,290 0.19$					
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Anesthesia $9,772,491 $22,003,254 0.776$			
Surgery,	Nervous	System $11,644 $26,218 0.001$			
Preventive	Medicine	Services $4,596 $10,347 0.000$			
Surgery,	Digestive	System $3,653 $8,224 0.000$			
Surgery,	Eye	&	Ocular	Adnexa $3,494 $7,866 0.000$			
Office/Other	Outpatient	Services $3,067 $6,905 0.000$			
Surgery,	Cardiovascular	System $2,859 $6,437 0.000$			
Radiology $2,074 $4,669 0.000$			
Surgery,	Female	Genital	System $2,068 $4,656 0.000$			
Drugs	Other	Than	Chemotherapy $1,725 $3,884 0.000$			
Surgery,	Musculoskeletal	System $1,300 $2,927 0.000$			
Hospital	Inpatient	Services $1,293 $2,911 0.000$			
Moderate	(conscious)	Sedation $1,068 $2,405 0.000$			
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	
Care	Services $825 $1,858 0.000$			
Cardiovascular $750 $1,689 0.000$			
Qualifying	Circumstances	for	Anesthesia $666 $1,499 0.000$			
Consultations $425 $957 0.000$			
Surgery,	Urinary	System $382 $861 0.000$			
Surgery,	Respiratory	System $256 $576 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $218 $492 0.000$			
Emergency	Department	Services $210 $473 0.000$			
Pulmonary $196 $441 0.000$			
Immunization	Administration	for	Vaccines/Toxoids $131 $295 0.000$			
Vaccines,	Toxoids $107 $241 0.000$			
Surgery,	Maternity	Care	&	Delivery $82 $186 0.000$			
Pathology	&	Laboratory $46 $104 0.000$			
Ophthalmology $6 $14 0.000$			
Unclassified	Services -$2,707 -$6,095 (0.000)$	
All	Services $9,812,925 $22,094,293 0.78$					
Comprehensive	Mandated	Benefit	Review		









Office/Other	Outpatient	Services $11,107,518 $25,009,134 0.882$					
Preventive	Medicine	Services $3,039,299 $6,843,134 0.241$					
Psychiatry $934,552 $2,104,191 0.074$					
Immunization	Administration	for	Vaccines/Toxoids $672,655 $1,514,516 0.053$					
Chemotherapy	Drugs $513,553 $1,156,290 0.041$					
Vaccines,	Toxoids $475,106 $1,069,724 0.038$					
Surgery,	Integumentary	System $435,571 $980,709 0.035$					
Drugs	Other	Than	Chemotherapy $263,777 $593,908 0.021$					
Allergy	&	Clinical	Immunology $262,762 $591,621 0.021$					
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $241,484 $543,712 0.019$					
Temporary	Procedures	&	Professional	Services $230,139 $518,170 0.018$					
Hospital	Inpatient	Services $223,490 $503,199 0.018$					
Emergency	Department	Services $210,139 $473,139 0.017$					
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	
and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	
Biologic	Agent	Administration $202,404 $455,722 0.016$					
Consultations $115,437 $259,912 0.009$					
Temporary	National	Codes	Est.	by	Medicaid $100,044 $225,254 0.008$					
Pathology	&	Laboratory $88,411 $199,062 0.007$					
Surgery,	Cardiovascular	System $78,101 $175,849 0.006$					
Surgery,	Musculoskeletal	System $64,701 $145,678 0.005$					
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	Care	
Services $50,337 $113,337 0.004$					
Surgery,	Respiratory	System $49,570 $111,609 0.004$					
Temporary	Codes	Assigned	by	CMS $33,266 $74,901 0.003$					
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	Mental	
Status,	Speech	Testing) $33,186 $74,721 0.003$					
Surgery,	Female	Genital	System $30,924 $69,626 0.002$					
Special	Otorhinolaryngologic	Services $27,710 $62,391 0.002$					
Surgery,	Urinary	System $27,235 $61,321 0.002$					
Home	Health	Procedures/Services $25,078 $56,463 0.002$					
Temporary	National	Codes	Est.	by	Private	Payers $25,070 $56,447 0.002$					
Cardiovascular $24,816 $55,874 0.002$					
Nursing	Facil ity	Services $20,998 $47,278 0.002$					
Pulmonary $20,552 $46,273 0.002$					
Surgery,	Digestive	System $17,243 $38,824 0.001$					
Hospital	Observation	Services $17,091 $38,481 0.001$					
Surgery,	Nervous	System $15,720 $35,393 0.001$					
Surgery,	Maternity	Care	&	Delivery $14,362 $32,336 0.001$					
Critical	Care	Services $14,178 $31,923 0.001$					
Surgery,	Auditory	System $14,034 $31,599 0.001$					
Newborn	Care	Services $14,031 $31,591 0.001$					
Photodynamic	Therapy $13,964 $31,441 0.001$					
Anesthesia $13,051 $29,386 0.001$					
Radiology $10,609 $23,887 0.001$					
Neurology	&	Neuromuscular	Procedures $9,732 $21,913 0.001$					
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Gastroenterology $6,780 $15,266 0.001$					
Physical	Medicine	&	Rehabilitation $6,733 $15,160 0.001$					
Special	Services,	Procedures,	and	Reports $4,732 $10,654 0.000$					
Medical	Nutrition	Therapy $4,199 $9,454 0.000$					
Orthotics $3,713 $8,360 0.000$					
Home	Services $2,929 $6,595 0.000$					
Endocrinology $2,377 $5,353 0.000$					
Surgery,	Male	Genital	System $2,111 $4,754 0.000$					
Surgery,	Eye	&	Ocular	Adnexa $1,600 $3,603 0.000$					
Prolonged	Services $1,462 $3,292 0.000$					
Special	Dermatological	Procedures $1,066 $2,399 0.000$					
Other	Services	&	Procedures $1,063 $2,394 0.000$					
Surgery,	Hemic	and	Lymphatic	Systems $945 $2,128 0.000$					
Noninvasive	Vascular	Diagnostic	Studies $742 $1,670 0.000$					
Immune	Globulins,	Serum,	or	Recombinant	Prods $638 $1,437 0.000$					
Surgery,	General $573 $1,290 0.000$					
Medical	&	Surgical	Supplies $448 $1,009 0.000$					
Durable	Medical	Equipment $410 $922 0.000$					
Health	&	Behavior	Assessment/Intervention $358 $806 0.000$					
Surgery,	Endocrine	System $289 $651 0.000$					
Ophthalmology $289 $651 0.000$					
Moderate	(conscious)	Sedation $152 $343 0.000$					
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	Services $142 $320 0.000$					
Administrative,	Miscellaneous	&	Investigational $108 $244 0.000$					
Chiropractic	Manipulative	Treatment $14 $32 0.000$					
Hearing	Services $13 $28 0.000$					
Unclassified	Services -$1,993 -$4,487 (0.000)$				
All	Services $19,823,794 $44,634,265 1.57$							
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Office/Other	Outpatient	Services $8,227,023 $18,523,554 0.653$	
Preventive	Medicine	Services $3,225,276 $7,261,871 0.256$	
Surgery,	Musculoskeletal	System $1,124,869 $2,532,698 0.089$	
Pathology	&	Laboratory $793,004 $1,785,488 0.063$	
Drugs	Other	Than	Chemotherapy $656,447 $1,478,023 0.052$	
Surgery,	Integumentary	System $536,993 $1,209,066 0.043$	
Vaccines,	Toxoids $505,590 $1,138,361 0.040$	
Psychiatry $369,187 $831,243 0.029$	
Hospital	Inpatient	Services $367,589 $827,645 0.029$	
Surgery,	Digestive	System $345,418 $777,726 0.027$	
Immunization	Administration	for	Vaccines/Toxoids $286,280 $644,574 0.023$	
Allergy	&	Clinical	Immunology $222,408 $500,762 0.018$	
Emergency	Department	Services $172,171 $387,652 0.014$	
Surgery,	Nervous	System $157,655 $354,968 0.013$	
Surgery,	Female	Genital	System $154,704 $348,324 0.012$	
Temporary	Procedures	&	Professional	Services $123,065 $277,086 0.010$	
Nursing	Facil ity	Services $122,731 $276,336 0.010$	
Surgery,	Maternity	Care	&	Delivery $110,779 $249,425 0.009$	
Hospital	Observation	Services $80,820 $181,970 0.006$	
Critical	Care	Services $74,723 $168,242 0.006$	
Temporary	National	Codes	Est.	by	Private	Payers $74,545 $167,842 0.006$	
Surgery,	Cardiovascular	System $69,213 $155,836 0.005$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $65,363 $147,169 0.005$	
Anesthesia $45,544 $102,545 0.004$	
Pulmonary $32,183 $72,461 0.003$	
Health	&	Behavior	Assessment/Intervention $31,346 $70,578 0.002$	
Temporary	Codes	Assigned	by	CMS $31,045 $69,899 0.002$	
Central	Nervous	System	Assessments/Tests	(Neuro-Cognitive,	
Mental	Status,	Speech	Testing) $28,644 $64,494 0.002$	
Surgery,	Urinary	System $16,307 $36,716 0.001$	
Cardiovascular $16,243 $36,573 0.001$	
Surgery,	Respiratory	System $15,327 $34,510 0.001$	
Surgery,	Auditory	System $14,065 $31,667 0.001$	
Special	Otorhinolaryngologic	Services $11,884 $26,758 0.001$	
Inpatient	Neonatal	Intensive,	and	Pediatric/Neonatal	Critical	
Care	Services $9,678 $21,790 0.001$	
Surgery,	Male	Genital	System $9,316 $20,976 0.001$	
Physical	Medicine	&	Rehabilitation $9,171 $20,650 0.001$	
Orthotics $8,038 $18,098 0.001$	
Unclassified	Services $7,614 $17,144 0.001$	
Special	Dermatological	Procedures $6,486 $14,603 0.001$	
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	
Services $5,400 $12,159 0.000$	
Radiology $4,566 $10,281 0.000$	
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Surgery,	Endocrine	System $4,460 $10,042 0.000$	
Special	Services,	Procedures,	and	Reports $4,411 $9,933 0.000$	
Consultations $3,889 $8,757 0.000$	
Medical	Nutrition	Therapy $3,883 $8,744 0.000$	
Behavioral	Health	and/or	Substance	Abuse	Treatment	Services $3,720 $8,376 0.000$	
Surgery,	Operating	Microscope $3,286 $7,398 0.000$	
Newborn	Care	Services $2,862 $6,445 0.000$	
Immune	Globulins,	Serum,	or	Recombinant	Prods $2,619 $5,897 0.000$	
Chemotherapy	Drugs $2,377 $5,351 0.000$	
Surgery,	Eye	&	Ocular	Adnexa $1,891 $4,259 0.000$	
Home	Services $1,854 $4,175 0.000$	
Surgery,	Hemic	and	Lymphatic	Systems $1,787 $4,024 0.000$	
Neurology	&	Neuromuscular	Procedures $1,516 $3,413 0.000$	
Medical	&	Surgical	Supplies $1,012 $2,278 0.000$	
Other	Services	&	Procedures $964 $2,171 0.000$	
Surgery,	Mediastinum	&	Diaphragm $845 $1,902 0.000$	
Prolonged	Services $693 $1,559 0.000$	
Durable	Medical	Equipment $648 $1,460 0.000$	
Photodynamic	Therapy $468 $1,053 0.000$	
Gastroenterology $352 $793 0.000$	
Surgery,	General $292 $658 0.000$	
Chiropractic	Manipulative	Treatment $35 $78 0.000$	
Temporary	National	Codes	Est.	by	Medicaid $15 $34 0.000$	
Laboratory	Services $10 $23 0.000$	
Administrative,	Miscellaneous	&	Investigational $0 $0 -$						
All	Services $18,212,602 $41,006,587 1.45$				
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Physical	Medicine	&	Rehabilitation $795,453 $4,087,950 0.466$	
Chiropractic	Manipulative	Treatment $603,976 $3,103,920 0.354$	
Office/Other	Outpatient	Services $139,158 $715,154 0.082$	
Radiology $11,883 $61,068 0.007$	
Psychiatry $464 $2,385 0.000$	
Temporary	Procedures	&	Professional	Services $320 $1,645 0.000$	
Medical	Nutrition	Therapy $130 $668 0.000$	
Osteopathic	Manipulative	Treatment $66 $341 0.000$	
Surgery,	Cardiovascular	System $22 $113 0.000$	
Ophthalmology $0 $0 -$						
Special	Services,	Procedures,	and	Reports $0 $0 -$						
All	Services $1,551,472 $7,973,244 0.91$				
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Durable	Medical	Equipment $55,029 $282,803 0.032$	
Office/Other	Outpatient	Services $53,189 $273,346 0.031$	
Dental	Procedures $50,663 $260,365 0.030$	
Surgery,	Musculoskeletal	System $32,024 $164,578 0.019$	
Temporary	National	Codes	Est.	by	Private	Payers $24,826 $127,584 0.015$	
Surgery,	Digestive	System $23,568 $121,119 0.014$	
Surgery,	Respiratory	System $10,174 $52,285 0.006$	
Physical	Medicine	&	Rehabilitation $7,472 $38,400 0.004$	
Radiology $4,656 $23,927 0.003$	
Pathology	&	Laboratory $3,996 $20,538 0.002$	
Hospital	Inpatient	Services $1,326 $6,812 0.001$	
Surgery,	Integumentary	System $1,146 $5,890 0.001$	
Surgery,	Female	Genital	System $1,000 $5,139 0.001$	
Surgery,	Nervous	System $472 $2,424 0.000$	
Moderate	(conscious)	Sedation $396 $2,037 0.000$	
Surgery,	Auditory	System $227 $1,169 0.000$	
Medical	&	Surgical	Supplies $80 $411 0.000$	
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	Highly	Complex	Biologic	Agent	Administration$32 $167 0.000$	
Drugs	Other	Than	Chemotherapy $0 $0 -$						
Temporary	National	Codes	Est.	by	Medicaid $0 $0 -$						
All	Services $270,277 $1,388,993 0.16$				
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Ophthalmology $1,070,692 $5,502,446 0.628$	
Office/Other	Outpatient	Services $81,961 $421,210 0.048$	
Vision	Services $34,101 $175,250 0.020$	
Temporary	National	Codes	Est.	by	Private	Payers $14,213 $73,043 0.008$	
Surgery,	Eye	&	Ocular	Adnexa $4,832 $24,831 0.003$	
Surgery,	Musculoskeletal	System $3,659 $18,806 0.002$	
Psychiatry $610 $3,134 0.000$	
Radiology $570 $2,928 0.000$	
Orthotics $497 $2,557 0.000$	
Neurology	&	Neuromuscular	Procedures $355 $1,826 0.000$	
Surgery,	Integumentary	System $329 $1,688 0.000$	
Physical	Medicine	&	Rehabilitation $213 $1,093 0.000$	
All	Services $1,212,032 $6,228,813 0.71$				
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Office/Other	Outpatient	Services $3,567,939 $8,033,394 0.283$			
Surgery,	Integumentary	System $1,680,783 $3,784,368 0.133$			
Surgery,	Musculoskeletal	System $1,221,009 $2,749,163 0.097$			
Orthotics $298,594 $672,300 0.024$			
Radiology $213,312 $480,282 0.017$			
Surgery,	Nervous	System $82,818 $186,469 0.007$			
Physical	Medicine	&	Rehabilitation $76,949 $173,254 0.006$			
Consultations $33,225 $74,807 0.003$			
Medical	&	Surgical	Supplies $24,132 $54,335 0.002$			
Drugs	Other	Than	Chemotherapy $23,549 $53,022 0.002$			
Hospital	Inpatient	Services $11,746 $26,448 0.001$			
Pathology	&	Laboratory $10,640 $23,956 0.001$			
Other	Services	&	Procedures $8,977 $20,213 0.001$			
Temporary	Codes	Assigned	by	CMS $5,553 $12,503 0.000$			
Temporary	Procedures	&	Professional	Services $5,103 $11,490 0.000$			
Temporary	National	Codes	Est.	by	Private	Payers $4,808 $10,826 0.000$			
Hydration,	Therapeutic,	Prophylactic,	Diagnostic	Injections	&	
Infusions,	and	Chemotherapy	&	Other	Highly	Complex	Drug	or	
Highly	Complex	Biologic	Agent	Administration $1,811 $4,078 0.000$			
Durable	Medical	Equipment $1,499 $3,376 0.000$			
Nursing	Facil ity	Services $1,474 $3,318 0.000$			
Prosthetics $1,223 $2,754 0.000$			
Home	Services $1,131 $2,548 0.000$			
Surgery,	Digestive	System $882 $1,986 0.000$			
Noninvasive	Vascular	Diagnostic	Studies $521 $1,174 0.000$			
Critical	Care	Services $334 $753 0.000$			
Domicil iary,	Rest	Home	(boarding	home)	or	Custodial	Care	
Services $326 $735 0.000$			
Preventive	Medicine	Services $307 $691 0.000$			
Transport	Services	Including	Ambulance $263 $592 0.000$			
Prolonged	Services $225 $507 0.000$			
Vaccines,	Toxoids $208 $468 0.000$			
Surgery,	Cardiovascular	System $96 $216 0.000$			
Immunization	Administration	for	Vaccines/Toxoids $83 $187 0.000$			
Chemotherapy	Drugs $82 $186 0.000$			
Emergency	Department	Services $75 $169 0.000$			
Special	Services,	Procedures,	and	Reports $56 $126 0.000$			
Neurology	&	Neuromuscular	Procedures $39 $89 0.000$			
Administrative,	Miscellaneous	&	Investigational $33 $73 0.000$			
Special	Otorhinolaryngologic	Services $12 $26 0.000$			
Unclassified	Services -$3,473 -$7,820 (0.000)$	
All	Services $7,276,347 $16,383,060 0.58$					
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Appendix	E:	List	of	Study	Acronyms	AAFP	 American	Academy	of	Family	Physicians	AAP	 American	Academy	of	Pediatrics	ABA	 Applied	Behavior	Analysis	ACA	 Patient	Protection	and	Affordable	Care	Act	ACIP	 Advisory	Committee	on	Immunization	Practices	ACOG	 American	College	of	Obstetrics	and	Gynecology	ACOG	 American	Congress	of	Obstetricians	and	Gynecologists	ACP	 American	College	of	Physicians	ACR	 American	College	of	Radiology	ACS	 American	Cancer	Society	ADDM	 Autism	and	Developmental	Disabilities	Monitoring	AHFS-DI	 American	Hospital	Formulary	Service-Drug	Information	AHRQ	 The	National	Guideline	Clearing	House	under	the	federal	Agency	for	Healthcare	Research	and	Quality	AMA	 American	Medical	Association	AMA-DE	 American	Medical	Association	Drug	Evaluations	APA	 American	Psychiatric	Association	APN	 Advanced	Practice	Nurse	APRN	 Advanced	Practice	Registered	Nurse	ART	 Assisted	Reproduction	Techniques	ASD	 Autism	Spectrum	Disorder	ASCP	 American	Society	for	Clinical	Pathology	ASCCP	 American	Society	for	Colposcopy	and	Cervical	Pathology	BDC	 Base	Direct	Cost	BLL	 Blood	Lead	Level	BMT	 Bone	Marrow	Transplant	C-Section	 Caesarean	Section	CAM	 Complementary	and	Alternative	Medicine	CDC	 Centers	for	Disease	Control	and	Prevention	CHIA	 Center	for	Health	Information	and	Analysis	CHT	 Combined	Hormone	Therapy	
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CIA	 Chemotherapy-Induced	Alopecia	CMS	 Centers	for	Medicare	and	Medicaid	Services	CNM	 Certified	Nurse-Midwife	COH	 Controlled	Ovarian	Hyperstimulation	CR	 Collaborative	Reanalysis	CR	 Cardiac	Rehabilitation	CRNA	 Certified	Registered	Nurse	Anesthetist	CVD	 Cardiovascular	Disease	DIR	 Developmental,	Individual	Differences,	Relationship-Based	Approach	DMEPOS	 Durable	Medical	Equipment,	Prosthetics,	Orthotics,	and	Supplies	DPA	 Diagnostic	Pharmaceutical	Agents	DPM	 Doctor	of	Podiatric	Medicine	DSM	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders	DSM-IV	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	4th	Edition	DSM-V	 Diagnostic	and	Statistical	Manual	of	Mental	Disorders,	5th	edition	DTT	 Discrete	Trial	Training	DVT	 Deep	Vein	Thrombosis	EHB	 Essential	Health	Benefit	EHDI	 Early	Hearing	Detection	and	Intervention	EIBI	 Early	Intensive	Behavioral	Intervention	EN	 Enteral	Nutrition	EPC	 Evidence-based	Practice	Center	EPSDT	 Early	and	Periodic	Screening,	Diagnosis	and	Treatment	ET	 Estrogen	Therapy	FDA	 Food	&	Drug	Administration	FEDVIP	 Federal	Vision	Insurance	Program	HDC-ABMT	 High-dose	Chemotherapy	plus	Autologous	Bone	Marrow	Transplant	HEN	 Home	Enteral	Nutrition	HHA	 Home	Health	Agency	HLA	 Human	Leukocyte	Antigen	HMO	 Health	Maintenance	Organization	HPV	 Human	Papillomavirus	
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HRSA	 Health	Resources	and	Services	Administration	HRT	 Hormone	Replacement	Therapy	HSC	 Health	Service	Corporation	HSCT	 Hematopoietic	(blood)	Stem	Cell	Transplants	ICSI	 Intracytoplasmic	Sperm	Injection	IDEA	 Public	Law	108-77:	Individuals	with	Disabilities	Education	Improvement	Act	(2004)	IVF	 In-Vitro	Fertilization	JCIH	 Joint	Committee	on	Infant	Hearing	Kuvan	 Sapropterin	Dihydrochloride	LPF	 Low	Protein	Food	MD	 Medical	Doctor	MDC	 Marginal	Direct	Cost	MDD	 Major	Depressive	Disorder	MEPS	 Medical	Expenditure	Panel	Survey	MSC	 Medical	Service	Corporation	MWS	 Million	Women	Study	NBEO	 National	Board	of	Examiners	in	Optometry	NCSBN	 National	Council	of	State	Boards	of	Nursing	NIDA	 National	Institute	for	Drug	Abuse	NMDP	 The	National	Marrow	Donor	Program	NP	 Nurse	Practitioner	NPA	 Non-Physician	Anesthetists	NPDC-ASD	 The	National	Professional	Development	Center	on	Autism	Spectrum	Disorder	PA	 Physician	Assistants	PAM	 Patient	Assessment	and	Management	PCHL	 Permanent	Congenital	Hearing	Loss	PECS	 Picture	Exchange	Communication	System	Phe	 Phenylalanine	PKU	 Phenylketonuria	PRT	 Pivotal	Response	Training	RDC	 Required	Direct	Cost	RN	 Registered	Nurse	
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SNF	 Skilled	Nursing	Facility	SNRI	 Selective	Serotonin/Norepinephrine	Reuptake	Inhibitors	SSRI	 Selective	Serotonin	Reuptake	Inhibitors	TEACCH	 Treatment	and	Education	of	Autistic	and	Related	Communication	Handicapped	Children	TMOD	 Treatment	and	Management	of	Ocular	Disease	TPA	 Therapeutic	Pharmaceutical	Agents	USP-DI	 United	States	Pharmacopoeia-Drug	Information	USPSTF	 U.S.	Preventive	Services	Task	Force	VBI	 Verbal	Behavior	Intervention	WHI	 Women’s	Health	Initiative		 	
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For more information, please contact:
CENTER FOR HEALTH INFORMATION AND ANALYSIS
501 Boylston Street 
Boston, MA  02116
617.701.8100
www.chiamass.gov
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